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The opioid field and the quest for the ideal analgesics with limited side 
effects has accumulated decades of research and thousands of new 
opioid compounds. However, in spite of the substantial advances in the 
understanding of opioid receptor pharmacology, the main stays of pain 
management remain to be mu analgesics such as morphine, fentanyl, 
and oxycodone, that exhibit the side effect profile - tolerance, 
dependence, constipation, respiratory depression, and euphoria resulting 
in abuse and addiction. The opioid response is mediated in conjunction 
by G protein and β-arrestin signaling pathways, where the G protein 
pathway is often linked to the therapeutic effect of the drug and the β-
arrestin pathway is linked to the side effects. More recently, the field has 
focused on developing biased agonists that activate only the subset of 
signaling pathways important for the therapeutic effect while limiting the 
unwanted side effects. Much of the recent work in the field has explored 
ligand bias at only the MOR-1 variant. However, the mu receptor gene, 
Oprm1, shows extensive alternative splicing and more than 60 different 
splice variants have been identified across different species. In this 
study, we explored the differences across the C-terminal variants of the 
mu opioid receptor and how these differences at the tip of the C-terminal 
tail might impact its ability to stimulate G protein coupling, β-arrestin 
recruitment, and ultimately, signal bias. In our comparisons across the 
the C-terminal variants, we were able to identify a C-terminal variant, 
MOR-1O which showed significant β-arrestin bias relative to MOR-1. The 
MOR-1O receptor variant contains exons 1, 2 and 3 like MOR-1, with 
splicing downstream of exon 3 where it has exon 7 instead of exon 4 in 
MOR-1. We were able to generate an exon 7 knockout mutant mouse 
model by introducing a stop codon at the 5’-end of exon 7 (E7) to stop 
translation at the end of exon 3 in variants that contain exon 7. 
Interestingly, the mE7M mice show a phenotype similar to the β-arrestin-
2 KO mice. These mE7M mice have no substantial difference in analgesic 
sensitivity or physical dependence but develop no tolerance in response 
to morphine. This provides a strong support for our in-vitro findings and 
suggests the functional interaction between the E7-associated C-terminal 
tails and β-arrestin-2. These findings are critical because they not only 
provide a potential target for therapeutic intervention to alleviate the 
morphine effects, but also, provides additional insights regarding the mu 
opioid receptor variants and their signaling biases to better screen for 
future new opioid analgesics.   
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Chapter I - Introduction 
 
The G-protein Coupled Receptor 
 
G-protein coupled receptors (GPCRs) constitute the largest family of 
cell surface receptors and are found in all eukaryotes. The diversity of 
GPCRs is represented by the multiplicity of stimuli to which they 
respond, as well as by the variety of intracellular signaling pathways 
activated by them. About half of all known drugs work through 
GPCRs, as they mediate the response to an enormous diversity of 
signaling molecules, including hormones, mediators and 
neurotransmitters. There are approximately 800 unique GPCRs, out of 
which, 460 have been predicted to be olfactory receptors (Fredriksson 
et al., 2003). Their primary function is to transduce extracellular 
stimuli into intracellular signal and are involved in the regulation of a 
wide variety of physiological processes like, the sensory perception of 
pain, light, cognition, inflammation and immunity.  
 
Despite the chemical and functional diversity of signaling molecules 
that bind to them, all GPCRs have a similar structure. Most of the 
initial structural insights about GPCR structure came from the 
rhodopsin family. Rhodopsin was easily obtained in large quantities 
from the bovine retina and was much more stable than most other 
GPCRs. The concentration of rhodopsin in rod outer segments is about 
3mM, which is orders of magnitude higher than that of typical 
hormone or neurotransmitter receptors (Stryer, 1986). Findlay and 
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Pappin first modeled rhodopsin in 1986 and soon after that, a number 
of other GPCR models were also published (Findlay et al., 1986; 
Burbach et al., 1992; Chou et al., 1992; Cronet et al., 1993). 
 
All GPCRs consist of seven trans-membrane (TM) segments with an 
extra-cellular amino terminus and an intra-cellular carboxyl terminus 
(Figure 1). The TMs are comprised of a single polypeptide chain that 
threads back and forth across the lipid bilayer. The TM segments show 
the greatest homology across GPCRs with the most differences at 
amino terminus, the carboxyl terminus and the intracellular loop 
spanning TM5 and TM6 (Pierce et al., 2002). Around this period of 
time in the 1980-90s, there was also a lot of ongoing effort towards 
developing amino acid similarity matrix methods. This enabled the 
characterization of the salient features of amino acid residues in the 
Figure 1 Seven trans-membrane receptor (Lefkowitz et al.,2000) 
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proposed TMs and helical regions of the receptors (Attwood et al., 
1991; Overington et al., 1992). These approaches helped provide a 
fingerprint for the helical regions of each GPCR and enabled clustering 
of the known receptor sequences into families and subtypes.  
 
The GPCRs have been clustered into 5 sub-categories based on their 
sequence similarity: the rhodopsin family (701 members), the adhesion 
family (24 members), the frizzled family (24 members), the glutamate 
family (15 members) and the secretin family (15 members). The 
rhodopsin family of receptors have short N-termini and bind peptide, 
amine and lipid like molecules in a ligand-binding pocket defined by 
the TM regions of the protein (Nordström et al., 2009). The adhesion 
family is the second largest GPCR family. These receptors are 
characterized by long serine and threonine-rich N-termini. It has been 
speculated that these long N-termini have a role in cell-to-cell 
communication (Bjarnadottier et al., 2007). The frizzled receptors have 
long cysteine-rich N-termini that interact with the curly twisted Wnt 
protein and have a role in cell polarity. The Glutamate GPCRs are 
characterized by the ‘‘Venus Flytrap’’ mechanism, which is found in 
the N-termini and is crucial for ligand binding. In the Secretin family, 
all GPCRs have a hormone-binding domain (HBD) in their N-termini 
that interacts with peptide hormones (Schioth et al., 2007).  
 
The β-adrenergic receptor for catecholamines became the prototype for 
the intense study of GPCRs, which lead to the unraveling of the 
structural basis of receptor function. A major part of the research that 
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ultimately led to the unraveling of the GPCR molecular structure came 
from the work of Earl Sutherland in the 1950s (Sutherland, 1971). 
Even though Sutherland’s work focused on studying the mechanism of 
phosphorylase activation by epinephrine and glucagon and the 
discovery of the ‘second messenger’ system rather than the receptor 
function itself, he viewed the β-adrenergic receptor for epinephrine as 
a regulatory component of the adenylyl cyclase system. He explored 
the relationship between the receptors and enzyme catalytic activity by 
focusing particularly on the β-adrenergic stimulation of adenylyl 
cyclase. In 1970s, the study of membrane receptors was transformed 
by the development of radio-ligand binding studies, which permitted 
the direct study of the receptors for the first time. Once the radio-
ligands were available, the challenge of purifying a functional adenylyl 
cyclase coupled receptor was undertaken.  
 
Another crucial advancement came with the successful development of 
an affinity chromatography matrix, which was used to couple a β-
adrenergic antagonist to agarose and purify the functionally active 
receptor. By 1982, the β2-adrenergic receptor was purified from 
amphibian erythrocytes and the β1-adrenergic receptor was purified 
from avian erythrocytes (Shorr et al., 1981; Shorr et al., 1982). 
Donnelly's three-dimensional model of the human β2-adrenergic 
receptor was used as the basis for construction of the GPCR models 
(Donnelly et al., 1989; Kobilka et al., 1992). These biochemical studies 
complemented Sutherland’s work and also lead the way towards 
separating the concept of receptors from the catalytic moiety of 
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adenylyl cyclase and provided evidence that the receptors could be 
found in agonist-driven complexes with G proteins (Haga et al., 1977; 
Limbird et al.,1977; 1978). 
 
All GPCRs are glycoproteins that have at least one consensus 
sequence for N-linked glycosylation (Asn-X-Ser/Thr) in the 
extracellular domain. These putative glycosylation sites are usually 
Figure 2 Primary structure of the hamster β2-adrenergic receptor showing 
the proposed topology of the seven transmembrane helices. The extracellular 
domain is at the top of the figure. Glycosylation sites are indicated with solid 
boxes. The boundaries of the eell membrane are represented by dashed 
lines. (Strader et al., 1994) 
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located near the N terminus of the protein, although occasionally there 
are potential sites in the second extracellular loop. Cloning and 
sequence determination of more members of β-adrenergic receptor 
family of receptor proteins showed that these receptors are 
characterized by seven hydrophobic stretches of 20-25 amino acids, 
predicted to form TM helices, connected by alternating extracellular 
and intracellular loops. Most of the primary sequence homology is 
contained in the hydrophobic TM regions of the GPCRs, whereas the 
hydrophilic loops show more divergence. The primary sequence 
identity in the TM domain of these receptors ranges from 85-95% for 
species homologs of a given receptor, 60-80% for related subtypes of 
the same receptor, 35-45% for other members of the same family and 
20-25% for unrelated GPCRs (Strader et al., 1994). 
 
GPCR Signal Transduction  
 
The classical paradigm of GPCR signal transduction suggests that 
conformational changes in the receptor arise upon ligand binding. This 
allows it to couple to the heterotrimeric G proteins and regulate 
downstream effector molecules. However, the activation of a GPCR by 
its ligand also initiates the process of receptor desensitization. 
Desensitization is an adaptive process used by cells to arrest G protein 
signaling, potentially, preventing the harmful effects that could result 
from persistent receptor stimulation. Waning responsiveness to 
continuous or repeated stimulation constitutes the phenomenon of 
desensitization. Almost every GPCR undergoes desensitization, and 
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despite their diversity, most GPCRs use a universal mechanism 
involving the coordinated action of two families of proteins, the G 
protein coupled receptor kinases (GRKs) and the arrestins (Freedman 
et al., 1996; Ferguson, 2001).  
 
G protein Signaling 
 
In the absence of an agonist, GPCRs exist in a low-affinity state. 
Agonist binding causes a conformational change that transforms 
GPCRs into a transient high-affinity complex comprising of the 
Figure 3 Schematic of GPCR signal transduction starts after agonist 
stimulation. Activated GPCR causes the dissociation of the heterotrimeric G 
protein that activates second messenger signaling. GRK 2/3 mediated β-
arrestin recruitment leads to the internalization of the receptor and can also 
lead to desensitization. GRK 5/6 mediated β-arrestin recruitment leads to 
the activation of β-arrestin dependent ERK pathways and other kinases. 
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agonist, activated receptor and the heterotrimeric GTP-binding 
proteins. The G proteins are attached to the cytoplasmic face of the  
plasma membrane, where they act as relay molecules while coupling 
the receptor to enzymes or ion channels (Pierce et al., 2002). The idea 
that guanine-nucleotide regulatory proteins functionally connect 
receptors with effectors was first conceived in 1971, by Martin Rodbell 
(Rodbell et al., 1971). However, it wasn’t until 1987, that the G protein 
was purified and shown to be heterotrimeric, comprising of α, β and γ 
subunits (Gilman et al., 1987). The β and γ subunits remain 
associated in a tightly linked complex.  The overall combination of α, β 
and γ subunits increases the combinatorial complexity of G-proteins. 
The α subunit is responsible for GTP and GDP binding and for GTP 
hydrolysis. So far, 16 α, 5 β and 12 γ proteins have been cloned. There 
are 4 main sub-families of the α subunit: Gs proteins cause the 
stimulation of adenylyl cyclase, Gi proteins cause the inhibition of 
adenylyl cyclase as well as the activation of G-protein-coupled 
inwardly rectifying potassium (GIRK) channels; Gq proteins couple to 
the activation of phospholipase Cβ; and G12 proteins couple to 
activation of Rho Guanine nucleotide exchange factors (GEFs) (Pierce 
et al., 2002).  
 
In the basal state, the α subunit is bound to a GDP and the G protein 
is in its inactive state.  The activated receptor acts as a Guanine 
nucleotide exchange factor (GEF) promoting the dissociation of GDP 
from the G protein and its replacement by GTP. The GDP-GTP 
exchange causes the dissociation of the heterotrimeric G-protein into α 
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subunits and βγ dimer, both of which can regulate separate effectors  
(Pierce et al., 2002).  
 
Table 1 G protein subunits and their functional effectors. (Pierce et al., 2002) 
G-protein subunits Effectors 
Gs Adenylyl cyclase 
Golf RGS-PXI, calcium channels, c-Src tyrosine 
kinases 
Gt cGMP phosphodiesterase 
Ggust Phosphodiesterases 
Gi1,2,3 Adenylyl cyclase, c-Src tyrosine kinase 
Go Rap1GAP1 
Gz Rap1GAP1 
Gq, G11, G14,15,16 Phospholipase C, LARG RhoGEF 
G12, G13 p115 RhoGEF, PDZ-RhoGEF, LARG RhoGEF 
Gβγ GIRK K+ channels, GRKs, Adenylyl cyclases, 
Phospholipases 
 
Eventually, the α subunit acts as a GTPase and hydrolyzes the GTP 
back to GDP and re-associates with the βγ to reform an inactive G 
protein. The GTPase activity of the α subunit is enhanced by the 
binding of a second protein called the regulator of G protein signaling 
(RGS) proteins. There are about 25 RGS proteins encoded in the 
human genome, each of which is thought to interact with a particular 
set of G proteins (De Vries et al., 2000; Ross et al., 2000).  
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G proteins act by modulating the levels of cyclic AMP (cAMP). cAMP 
was first identified as a small intracellular mediator in the 1950s 
(Sutherland, 1971). It was while studying the mechanism of 
phosphorylase activation by epinephrine and glucagon that 
Sutherland succeeded in establishing the first cell preparations in 
which hormonal effects could be observed. These systems led him to 
the discovery of the ‘second messenger’ responsible for the actions of 
these hormones, cAMP, and to the enzyme responsible for its 
formation, adenylyl cyclase. Adenylyl cyclase is a large transmembrane 
protein with its catalytic domain on the cytosolic side of the plasma 
membrane. Once synthesized, cAMP is rapidly hydrolyzed by cAMP 
phosphodiesterases to adenosine 5’-monophosphate (5’-AMP). The 
normal concentration of cAMP inside the cell is about 10-7M, but an 
extracellular signal can cause the cAMP levels to change by more than 
20 folds in seconds (Lefkowitz et al., 2000).  
 
All GPCRs that are coupled to stimulatory Gs proteins, activate 
adenylyl cyclase and increases cAMP concentration. Inhibitory Gi 
proteins inhibit adenylyl cyclase and usually act by directly regulating 
ion channels rather than by decreasing cAMP content. cAMP can 
directly activate certain types of ion channels. However, it exerts most 
of its effects by activating cAMP-dependent protein kinase (PKA). PKA 
catalyzes the transfer of terminal phosphate group from ATP to specific 
serines or threonines of selected target proteins, thereby regulating 
their activity. PKA consists of a complex of 2 catalytic and 2 regulatory 
subunits. The binding of cAMP to the regulatory subunits alters their 
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conformation, causing them to dissociate from the complex. The 
released catalytic subunits can also phosphorylate downstream 
substrates.  
 
GRK-mediated regulation 
 
G protein receptor kinases (GRKs) are known to phosphorylate the 
activated or the agonist-occupied conformation of the receptor, 
thereby, mediating homologous or agonist-specific desensitization. The 
agonist-occupied receptor gets phosphorylated after the GRK kinases 
are recruited to the plasma membrane and form a complex with the 
receptor. The GRKs are encoded by a family of seven genes, GRK1-
GRK7. They have been divided into three subfamilies: the first consists 
of GRK1 and GRK7. GRK1 and GRK7 are confined to the retinal rods 
and cones, respectively. The second subfamily consists of the 
pleckstrin homology domain-containing GRK2 and 3, which interact 
with the βγ subunits of G proteins and phosphatidylinositol 4,5-
bisphosphate. The third group consists of GRK 4, 5 and 6. These 
GRKs remain constitutively associated with the plasma membrane 
through covalent attachment of either fatty acids or isoprenes to their 
carboxyl termini. Although the GRKs do show some receptor 
specificity, they are present fairly widely distributed and regulate a 
large, overlapping portfolio of receptors (Moore et al., 2007).  
 
GRKs phosphorylate the agonist-activated receptor at specific serine 
and threonine residues located in the C-tail and the third intracellular 
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tail. Phosphorylation by GRKs promotes binding of an arrestin 
molecule to the receptor while, also uncoupling the receptor from its 
respective G proteins. Several studies have suggested that GRK2 is 
often the major GRK associated with signal termination (Figure 3). 
However, the absence of subtype specific inhibitors for GRKs and the 
fact that GRK2 knockout mice are embryonically lethal has made 
determining the specificity of its action difficult to understand.  
 
Table 2 GRK mutations and their functional consequences (Moore et al., 
2007) 
GRK Target GPCR Phenotype 
GRK1 Rhodopsin Prolonged response of retinal cells to light 
GRK2 Unknown Embryonic lethality 
GRK2(-/+) β1/ β2 - AR Enhanced cardiac contractility to 
isoproterenol 
GRK3 Odorant 
receptor 
Muscarinic 
Olfactory supersensitivity, Enhanced 
airway response to methacholine 
GRK5 M2 
muscarinic 
 D1 dopamine 
 5-HT1A, 
CXCR4 
Enhanced hypothermia, hypoactivity, 
central cholinergic supersensitivity 
GRK6 CXCR4 Impaired lymphocyte chemotaxis 
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Several studies have tried to use small interfering RNAs (siRNA) to 
inhibit individual GRKs to better understand their specific function. 
This approach helped characterize that GRK2 and -3 are primarily 
responsible for agonist- dependent receptor phosphorylation, β-
arrestin recruitment and functional uncoupling, whereas GRK5 and -6 
make lesser contributions to this outcome (Kim et al., 2005; Ren et al., 
2005). Another recent siRNA study demonstrated that H1 histamine 
receptor desensitization is mediated by endogenous GRK2 but not 
GRK5 (Iwata et al., 2005). However, GRK5 and -6 have also been 
implicated in various examples of receptor desensitization in vivo 
and/or in vitro (Gainetdinov et al., 1999; Gainetdinov et al., 2003). 
 
Second-messenger kinase regulation  
 
Phosphorylation of GPCRs by other protein kinases like PKA, PKC and 
c-Src can also serve as negative feedback regulators and uncouple the 
receptor from its respective G proteins. They can also regulate 
heterologous forms of desensitization in which kinase activation by 
one type of receptor can lead to phosphorylation and desensitization of 
another receptor. For example, it was shown that in the β-adrenergic 
receptor, PKA mediated receptor phosphorylation switches the receptor 
away from Gs and enhances Gi coupling (Daaka et al., 1997; Zamah et 
al., 2002). This facilitates Gi-coupled pathways such as stimulation of 
the extracellular signal related kinase (ERK) and mitogen-activated 
protein kinase (MAPK) pathway.  
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β-arrestin mediated signaling  
 
The arrestins constitute of a four-member family. The arrestin 1 and 
arrestin 4 are expressed in the retinal rods and cones respectively. 
Arrestin 2 and 3 (also knows as β-arrestin 1 and 2), on the other hand, 
are present ubiquitously with highest levels of expression in the brain 
and spleen. The differential effects of visual arrestins and β-arrestins 
on GPCR endocytosis is influenced by the C-terminal tail of the 
molecule. β-arrestins, but not the visual arrestins, show affinity for 
clathrin in vitro. This happens through the binding of an LIEF  
 
 
 
sequence (residues 374-377 of β-arrestin2) to a N-terminal region of 
the clathrin heavy chain (residues 89-100)  (Goodman et al., 1996; 
Krupnick et al., 1997). β-arrestin2 can also directly bind β2 adaptin 
subunit of the AP-2 adaptor complex. The AP-2 complex plays a 
Figure 4 β-arrestin structure 
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critical role in linking GPCRs to the clathrin endocytic machinery by 
binding to clathrin, dynamin, and EPS-15 and initiating receptor 
endocytosis (Kirchhausen, 1999). 
 
Knockout animal models have been used to study the importance of β-
arrestins in the regulation of GPCR function in vivo. It has been shown 
that a β-arrestin1 knockout animal is developmentally normal and 
exhibits normal cardiac parameters. However, the stimulation of the β-
adrenergic receptor in this animal produces an exaggerated 
hemodynamic response (Conner et al., 1997). This indicates that β-
arrestin1 plays a role in cardiac β-adrenergic receptor desensitization. 
Similarly, in a homozygous β-arrestin2 knockout animal, it has been 
shown that analgesic effect of morphine is prolonged in these animals 
with an inability to develop tolerance (Bohn et al., 1999; Bohn et al., 
2000) 
 
Table 3 β-arrestin mutation and their functional consequence 
GRK Target GPCR Phenotype 
Arrestin Rhodopsin Prolonged photoresponse in retinal rods 
β-arrestin 1 β1/ β2 - AR Enhanced contractility in response to 
isoproterenol 
β-arrestin 2 Mu opioid 
CXCR4 
Prolonged morphine analgesia and 
reduced tolerance 
Impaired lymphocyte chemotaxis 
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All members of the family can bind to agonist-occupied receptor that 
has been phosphorylated by GRKs. Arrestin binding is known to 
sterically block the receptor-G protein interaction and plays a critical 
role in the process of homologous desensitization. In addition to their 
role in GPCR desensitization, β-arrestins also act as adapter proteins 
that regulate endocytosis and target GPCRs to clathrin coated pits. 
This process of GPCR sequestration not only plays a role in 
desensitization of the GPCR in the continued presence of an agonist, 
but also, in receptor resensitzation and downregulation. β-arrestins 
are also known to bind to other proteins involved in signal 
transduction like the Src family kinases, ERK 1/2 and JNK3 MAP 
kinase cascades.  
 
Desensitization of the receptor is a process that begins within seconds 
of agonist exposure and is initiated by phosphorylation of the receptor. 
Protein kinases like PKA and PKC, phosphorylate distinct serine and 
threonine residues in the C-terminal tail. As demonstrated with the 
β2-adrenergic receptor, the phosphorylation of C-tail by PKA, even in 
the absence of arrestins, is enough to impair receptor-G protein 
coupling (Benovic et al., 1985). The β2-adrenergic receptor kinases, 
GRK2 and GRK3, have C-terminal Gβγ subunit binding and pleckstrin 
homology domains, and they translocate to the membrane as a result 
of interactions between these domains and free Gβγ subunits and 
inositol phospholipids. The role of GRK phosphorylation is to increase 
the affinity of the receptor for arrestins (Lohse et al., 1993). There are 
several studies to suggest that receptor internalization and 
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dephosphorylation is required for the resensitization of many GPCRs 
(Sibley et al., 1986; Ferguson et al., 2001). With the β2-AR, it was seen 
that knocking out β-arrestin1/2 in a double knockout MEFs prevents 
the downregulation of the receptor (Kohout et al., 2001). 
 
Even though arrestins play a role in the agonist-promoted 
internalization of a GPCR, the extent of β-arrestin involvement varies 
significantly depending on the receptor, agonist and cell type. For 
example, a study by Oakley et al. demonstrated that both β2-
adrenergic receptor and vasopressin V2 receptor recruit β-arrestin. 
However, β2-adrenergic receptor recycles and resensitizes rapidly, 
whereas, V2R is known to recycle and resensitize slowly. This 
difference between the receptors was reversed when C-terminal tails of 
the two receptors was switched. These results indicated that the 
interaction of the β-arrestin with a specific motif in the C-tail dictates 
these effects (Oakley et al., 1999). Some of these differences could also 
be a result of differences in endogenous expression pattern of GRKs 
and β-arrestins and the availability of alternative pathways for GPCR 
endocytosis. 
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Mu Opioid Receptor  
 
Clinical Relevance  
 
Pain is a pervasive problem throughout medicine and opiates remain 
the most widely used analgesics in its treatment. Chronic pain affects 
more Americans than heart disease, cancer, and diabetes combined 
and is a major cause of visits to primary care physicians. Opioid 
alkaloids and related pharmaceuticals are the most effective analgesics 
for the treatment of acute and chronic pain and represent the largest 
market share of prescription pain medications (Melnikova, 2010). Out 
of the different classes of opioids, the mu receptor is the main opioid 
target for the management of pain. Opioid drugs such as morphine, 
fentanyl, and oxycodone are widely used clinically as powerful pain 
relievers. Due to their long history and proven efficacy, these mu 
opioids are the mainstay in the management of moderate to severe 
acute and chronic pain.  
 
However, despite the efficacy and utility of these opioid analgesics, 
side effects such as respiratory depression, inhibition of 
gastrointestinal transit, addiction, physical dependence and tolerance 
limit the utility of most currently used opiates (Cherny et al., 2001). In 
addition to the side effects, prescription opioids are also currently the 
most commonly abused drugs in the United States. According to 
recent statistics, 44 people die from prescription opioid overdose each 
day, which is greater than deaths from heroin and cocaine combined 
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(Kochanek et al., 2015). The ability of opioids to alleviate pain as well 
as produce euphoria has led to elevated rates of opioid prescriptions, 
use, misuse, hospitalizations, overdoses, and abuse in the last decade. 
Not only that, major depression, post-traumatic stress disorder, and 
anxiety disorders are more prevalent in patients who suffer from 
chronic pain (McWilliams et al., 2003).  
 
There is a significant unmet need for strong analgesic drugs with 
improved side effect profiles (Moskovitz et al., 2011). As a result, there 
is a lot of ongoing effort in the field to develop better analgesics that 
continue to provide the therapeutic pain relieving effect of opioids 
while minimizing some of the associated side effects. Decades of work 
in the opioid field has repeatedly demonstrated the heterogeneity of 
opioid receptor targets. We believe that a better understanding of the 
receptor multiplicity and their downstream signaling targets would 
facilitate the development of a new generation of opioid drugs that 
could provide pain relief with fewer side effects. 
 
Discovery and Cloning of the Mu Opioid Receptor 
 
In the early 1900s, physiologists such as Langley and Ehrlich first 
proposed the existence of entities understood as receptors, which 
bound and mediated the actions of drugs. The history of opioid 
receptor pharmacology, specifically, complements the history of the 
radioligand binding assay. The first proposal for the existence of opioid 
receptors came in the 1950s when several groups looked at the 
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structure-activity relationships of the opiates (Beckett et al., 1954; 
1956; Portoghese, 1966). Subsequently, Goldstein et al. tried to use 
[3H]levorphanol and its inactive enantiomer to demonstrate the 
existence of a stereo-selective receptor for opiates. They were, however, 
unsuccessful due to the low specific activity of the radioligand. It 
wasn’t until 1973 that 3 groups - Pert and Snyder, Simon et al, and 
Terenius, individually demonstrated the existence of opioid receptors 
in the mammalian central nervous system using radioligand binding 
assays with [3H]naloxone, [3H]dihydromorphine and [3H]etorphine 
respectively (Pert and Snyder, 1973; Simon et al., 1973; Terenius, 
1973). The biologically active (-)-enantiomers of methadone, 
levallorphan, and levorphanol competed this binding with very high 
affinity while the inactive (+)- enantiomers exhibited dramatically lower 
affinity for the opioid binding site. This confirmed the identity of the 
site as the target mediating the physiological effects of opioid drugs. 
 
Soon after the initial demonstration of opiate binding, additional 
studies revealed biochemical properties of opioids. Collier et al. 
reported the ability of opioid agonists to regulate the intracellular 
cAMP level in brain homogenates (Collier et al., 1974). Sharma et al. 
substantiated these finding in a cell line model using NG108-15 cells. 
Acute activation of the opioid receptor resulted in a Pertussis toxin 
(PTX) sensitive decrease in the intracellular cAMP levels. Chronic 
activation of the receptor, however, resulted in an increase of the cAMP 
levels when the agonist was removed (Collier, 1980). The inhibition of 
adenylyl cyclase regulated by the opioid receptor was mediated by Gi, 
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Go or Gz subunits. Pert et al. were further able to discriminate 
between agonist and antagonist binding to the receptor in vitro. They 
reported that sodium decreased agonist binding but increased 
antagonist binding (Pert et al., 1973). 
 
Cloning of µ-OR happened in 1993 shortly after the cloning of the 
delta opioid receptor. Interestingly, it happened using a cDNA probe 
for mouse DOR-1 TM3 with low hybridization stringency. When this 
DOR cDNA was transfected into COS-7 cells, it conferred the µ-OR 
binding site that had sub-nanomolar affinity for [3H]diprenorphine and 
nanomolar affinity for [D-A1a2,N-Me-Phe4,Gly-ol5]-enkephalin 
(DAMGO) (Chen et al., 1993). Further characterization of this binding 
site showed that binding was competed with high affinity by mu-
selective small molecules such as naloxonazine, β-funaltrexamine, and 
cyprodime, while the delta- selective peptides DPDPE and DSLET and 
kappa-selective small molecule U50,488 had dramatically lower 
affinity. These COS-7 cells expressing MOR-1 when treated with 
DAMGO, showed a decrease in the steady state levels of cAMP after 
forskolin stimulation. Soon after this, a number of other labs also 
reported sequences of the mu receptor (Eppler et al., 1993; Fukuda et 
al.,1993; Thompson et al., 1993; Wang et al., 1993). 
 
The mu receptor comprises of four exons yielding the seven TM 
structure of a traditional GPCR. The first exon encodes the N-terminus 
and the first TM domain while the second and third exons each 
encoded an additional three TM domains. The fourth exon is  
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responsible for coding only 12 amino acids at the tip of the 
intracellular C-terminus. Over the years, more than 60 splice variants 
have been isolated (Pasternak and Pan, 2013), out of which: there are 
31 variants from mice (Doyle et al., 2006, 2007; Pan et al., 1999, 
2000, 2005), 16 variants from rats (Zimprich et al., 1995, Pasternak et 
al., 2004; Xu et al., 2011;) and 19 variants from humans (Bare et al., 
1994; Cadet et al., 2003; Pan et al., 2003; Pan, 2005; Choi et al., 
2006; Xu et al., 2009). 
Figure 5 Gene Structure of Mouse, Rat, and Human Mu Opioid Receptor 
(OPRM-1). OPRM-1 undergoes extensive splicing, and exon structure is 
largely conserved across mammalian species. Boxes indicate exons and 
arrows indicate promoters. Genomic distances are indicated but are not to 
scale. Reproduced from (G. W. Pasternak & Pan, 2013). 
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Mu Opioid Receptor Multiplicity 
 
The opioid field is unique with respect to the availability of extensive 
clinical data for a wide range of drugs even prior to the identification of 
the receptors. Clinicians have known for a long time that the opioids 
do not work equally well in every patient. Some patients respond better 
to certain drugs. The side effect portfolio also varies from patient to 
patient (Foley et al., 1985, 1996). In addition, opioids show incomplete 
cross-tolerance such that a patient who is highly tolerant to one mu 
opiate can be switched to another opiate at a lower dose (Cherny et al., 
2001). These pharmacological observations cannot be reconciled with 
the existence of a single receptor and suggest the existence of multiple 
mu sites. 
 
The first experimental evidence for multiple opioid receptors came 
from binding studies by Wolozin and Pasternak that revealed a second 
morphine binding site. They observed a biphasic displacement curves 
and non-linear Scatchard plots indicating heterogeneity in the mu 
binding site and named the two mu binding sites as mu1 and mu2 
(Wolozin et al., 1981). It was proposed that the mu1 site binds opiates 
and enkephalins with high affinity (less than 1nM) and is irreversibly 
blocked by the antagonist naloxazone. The mu2 site, on the other 
hand, had lower affinity and selectively binds morphine with greater 
potency than several enkephalin analogs. In addition, it was also 
shown that mu1 and mu2 binding sites had distinct regional 
localization. Mu1 is thought to be associated with supraspinal 
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analgesia, whereas, mu2 is associated with respiratory depression and 
inhibition of gastrointestinal transit (Goodman et al., 1985, 1985a; 
Pasternak et al., 1983; Pasternak et al., 1986). Differences between the 
mu1 and mu2 sites were also demonstrated using [3H]-DADL binding 
where it was observed that 80% of the binding did not correspond to 
classical mu or delta sites. The binding was sensitive to DAMGO and 
morphine and insensitive to DPDPE, confirming its mu-like nature 
(Clark et al., 1989). However, in the thalamus, both µ-OR and δ-OR 
selective ligands competed this binding with high affinity, which 
suggested [3H]-DADL displayed selectivity for the mu1 site. The 
molecular identity of this site has not been identified. 
 
Antisense mapping and Knockout Mice 
 
Soon after the cloning of µ-OR, antisense knockdown studies were 
used to target receptor subtypes and understand the contribution of 
specific exons in the gene to the pharmacology. Antisense mapping 
involves the use of short oligodeoxynucleotides complementary to a 
targeted portion of mRNA to downregulate a gene product. These 
studies complement the antagonism studies but have the advantage of 
being more selective for the target gene. Depending on the abundance 
of the target mRNA, the antisense strategy typically reduces the 
protein levels by 25-50% and is reversible within 5 days after the final 
antisense treatment. This is consistent with estimates of 
approximately 3-5 day turnover times for opioid receptors (Ward et al., 
1982; Standifer et al., 1994). However, a limitation of the antisense 
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strategy is that it requires multiple pretreatments with the antisense 
oligodeoxynucleotide.  
 
Antisense studies of µ-OR supported previous pharmacological data 
indicating that not all mu agonists produce analgesia through the 
same molecular mechanism. For example, Morphine and M6G have 
similar affinity for the receptor; however, M6G is 100 fold more potent 
in its analgesic effects when given by an intracerebroventricular 
injection (Pasternak et al., 1987). Despite the presence of only one mu 
opioid receptor gene, the strict exon boundaries observed by antisense 
mapping suggests that alternative splicing could explain the 
pharmacological differences observed between morphine and M6G.  
 
The Pasternak group utilized antisense oligonucleotides (ODNs) 
directed against the 5’-untranslated region of µ-OR clone (Rossi et al., 
1994) and confirmed that the loss of these single genes alone was 
sufficient to impair analgesia of morphine. Rossi et al. demonstrated 
that antisense ODNs targeted to exons 1 and 4 blocked supraspinal 
morphine analgesia, while ODN’s targeted to exons 2 and 3 failed to 
have any significant effect (Rossi et al., 1995). In contrast, supraspinal 
M6G analgesia was blocked by antisense ODNs targeted to exons 2 
and 3 but not exons 1 and 4. Klein et al. observed similar results 
where exons 1 and 4 attenutated morphine but not heroin analgesia. 
Exon1 antisense also attenuated naloxone precipitated withdrawal 
from morphine and heroin (Klein et al., 2009). Another study in mice 
showed that ODNs against exon 2 blocked M6G, heroin, fentanyl and 
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etonitazine analgesia but had no effect on morphine (Rossi et al., 
1996). With the subsequent discovery of mouse Oprm1 exons 6, 7, 8, 
9, and 10, it was shown that antisense knockdown of these exons 
attenuated morphine but not M6G analgesia.  
 
Multiple groups also examined endomorphin analgesia using antisense 
mapping and found some interesting results. Intrathecal antisense 
directed against exons 1 and 4 attenuated both endomorphin 1 and 
endomorphin 2 analgesia. Exon 8 antisense only attenuated 
endomorphin 1 analgesia and had no effect on endomorphin 2. 
Interestingly, however, supraspinal antisense directed against exon 1, 
but not exons 2 and 4, attenuated endomorphin 1 analgesia. Spinal 
and supraspinal endomorphin 1 and 2 analgesia were significantly 
attenuated by antisense directed against µ-OR exons 1, 2, 3, 4, 5, 7, 8, 
9 but not exon 6 (Abbadie et al., 2002; Sanchez et al., 1999; Wu et al., 
2002). Overall, these findings support the proposal that alternative 
splicing of the receptor leads to different receptor variants which 
regulate mu analgesics. 
 
Mu Opioid Receptor Splice Variants 
 
The mu opioid receptor gene Oprm1 has been identified in more than 
30 vertebrate species ranging from non-mammalian vertebrates to 
humans (Figure 5). Mu opioid receptor gene homologues evolved early 
in vertebrate evolution, appearing first in teleosts as a gene comprised 
of 5 exons, each encoding a portion of the 7 TM domains that make up 
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the receptor (Herrero-Turrion & Rodríguez, 2008). Beginning in 
zebrafish, the introns separating exons 3-5 disappear to form a gene of 
3 exons. A 4th exon was first seen in the chicken. This 4 exon 
structure is conserved across amphibian, reptile, and mammalian 
species, and share >71% amino acid identity. Exon 1 encodes for the 
extracellular N-terminal region as well as the first trans-membrane 
domain. Exon 2 encodes trans-membrane 2, 3 and 4. Exon 3 encodes 
trans-membrane 4, 5 and 6 as well as a significant portion of the C-
tail. Exon 4 encodes the tip of the intracellular portion of the C-tail. 
Exon 4 is the major 3’ exon in the C-terminus of MOR-1 in most 
species. Exon 11 is the major exon associated with 5’ splicing. It has 
been identified in multiple mammalian species including rats and 
humans (Xu et al., 2009, Xu et al., 2011). 
 
Although pharmacological approaches have distinguished between mu 
subtypes, only a single gene has been identified for the mu opioid 
receptor. The promoter associated with exon 11 is located upstream of 
exon 1 and has two active regions that are conserved in mouse and 
human (Xu et al., 2001; Xu et al., 2001) The promoter shares 
similarities with “housekeeping genes,” as it contains high GC content 
and lacks a TATA box204. The gene is also under epigenetic control. 
The exon 1 promoter undergoes DNA methylation and histone 
modifications that can activate or silence the gene (Hwang et al., 2007; 
Hwang et al., 2009). The mouse OPRM1 gene contains at least 18 
different exons spanning over 270 kb.  
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Figure 6 Mouse Oprm1 gene structure and alternative splicing. Oprm1 
gene structure. Exons and introns are indicated by color-coded boxes 
and black horizontal lines, respectively. Promoters are showed by red 
arrows. Exons are numbered based upon the published data. Three 
classes of alternative splice variants, C-terminal full-length 7-TM 
variants, truncated 6-TM variants and truncated 1-TM variants, are 
indicated, and their predicted protein structures shown by cartoon 
inserts on right, in which color-coded structures match with 
corresponding color-coded exons (E). (Pasternak and Pan., 2013)   
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Three sets of µ-OR variants have been identified in rodents and 
humans. The first is the C-terminal variants. These are full-length 
7TM variants that all contain exons 1,2, and 3 encoding the N-
terminus and all the TM domains with splicing at the 3’ end. The 
second set involves the exon-11 associated variants with splicing in 
the 5’ end. Some of the exon-11 variants generate truncated 6TM 
receptor because of the absence of exon 1. The last set comprises the 
truncated variants with only a single TM domain encoded by exon 1. 
 
C-terminal Splice Variants 
 
C-terminal splice variants are all full-length variants that share exons 
1, 2 and 3 with splicing downstream of exon 3. Although many of the 
variants share exon 3, the amino acid sequence downstream of exon 3 
is unique for each variant due to reading-frame shifts or early 
termination. The length of the C-terminus in the C-terminal variants 
varies extensively with only 2 amino acids in mMOR-1B5 to 88 amino 
acids mMOR-1U. Since the MOR1 binding pocket is defined by TM 3, 
5, 6 and 7; all of the C-terminal variants contain an identical binding 
pocket. As a result, all of the mu opioids have high affinity for all the 
C-terminal splice variants.  
 
The splicing in rat and humans show some slight differences. For 
example, the alternative splicing of exon 5 generates 5 different 
variants in the mouse (mMOR-1B1 through mMOR-1B5), two variants 
in rats (rMOR-1B1 and rMOR-1B2), and five in humans (hMOR-1B1 
 30 
through hMOR-1B5) with different C-terminal amino acid sequences 
depending on which splice site is used in exon 5 (Pan et al., 2005). 
 
The splice variants are expressed in a very heterogeneous fashion. 
Some of the earlier studies examined the anatomical distribution of µ-
OR mRNA in the brain. However, our current knowledge about the 
splice variants raises some questions regarding those results as most 
of the splice variants share some common exons. As a result, the 
mRNA probes might be labeling more than one species of mRNA 
(Mansour et al., 1994, Minami et al., 1995, Zhu et al., 1998). Regional 
differences in the expression pattern of these splice variants have also 
been established through semi-quantitative RT-PCR analysis. In 
mouse brain, it was shown that the thalamus has a higher level of 
expression of mMOR-1C and little expression of mMOR-1D and 
mMOR-1E mRNAs. The striatum and hypothalamus highly express 
mMOR-1E mRNA, whereas mMOR-1D has higher expression in the 
cortex, brain stem and periaqueductal gray.  
 
 
Functional Differences 
 
More than 20 different C-terminal splice variants of the mu receptor 
have been identified in mouse. The C-terminal splice variants of µ-OR 
differ in their regional distribution, agonist induced G protein coupling 
(as measured by [35S]GTPγS binding), receptor phosphorylation, 
internalization and post-endocytic sorting. Spliced amino acid 
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differences at the C- terminus influence the ability of the opioids to 
activate the receptor independent of their receptor binding affinities.  
 
Functional differences among the variants have been demonstrated 
using [35S]GTPγS binding and adenylyl cyclase coupling. Zimprich et 
al. demonstrated that the functional coupling to adenylyl cyclase 
desensitizes at a slower rate in the MOR-1B variant, with a shorter C-
tail, than in MOR-1. Pretreatment of the cells expressing the rMOR-1 
variant showed a faster attenuation of the agonist induced inhibition 
of adenylyl cyclase in comparison to rMOR-1B variant. In addition to 
adenylyl cyclase, DAMGO induced desensitization measured as a 
decay of the opioid activated GIRK current, was also found to be much 
slower in MOR-1B than in the MOR-1 and MOR-1A variants (Oldfield 
et al., 2008). Another study in Human Embryonic Kidney 293 (HEK) 
cells showed similar results, where cells expressing the MOR-1B 
receptor desensitized at a slower rate during prolonged DAMGO 
exposure but re-sensitized at a faster rate than MOR-1 during agonist 
withdrawal. The same study also provided immunocytochemical 
evidence to show that DAMGO-induced internalization of MOR-1B 
happens much faster than that of MOR-1. Internalization is followed 
by rapid recycling of the receptor to the cell surface (Koch et al., 1998). 
Studies have shown in MOR-1, that the recycling of the receptor back 
to the cell surface following agonist-induced internalization is 
facilitated by the presence of an endocytic recycling sequence 
(Tanowitz et al., 2008)  
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The C-terminal differences of the variants are also associated with 
varying effects on efficacy and potency of the mu drugs. In Bolan et al., 
many mu opioids exhibited significant differences in their maximal 
stimulation relative to DAMGO across the different C-terminal splice 
variants of m µ-OR. β-endorphin stimulated [35S]GTPγS binding in the 
MOR-1E expressing cells to a much greater degree (130%) than 
DAMGO, however in MOR-1C expressing cells, it displayed a maximal 
stimulation of only 44% (Table 4).  
 
Table 4 Effects of opioids on [35S]GTPϒS binding in MOR-1 splice variants. 
Adapted from Bolan et al., 2004   
  MOR-1 MOR-1A 
  Ki EC50 % max Ki EC50 % max 
DAMGO 1.7 ± 0.4 68 ± 4 100 1 ± 0.3 70 ± 3 100 
Morphine 5.3 ± 2.5 23 ± 2 102 ± 5 3.1 ± 0.5 19 ± 4 91 ± 2 
M6G 6.4 ± 2.4 75 ± 18 122 ± 9 5 ± 1.5 114 ± 78 85 ± 9 
Methadone 1.4 ± 0.1 73 ± 12 87 ± 9 0.7 ± 0.1 14 ± 3 90 ± 13 
Fentanyl 2.3 ± 1.0 16 ± 2 145 ± 16 1.5 ± 0.6 60 ± 3 105 ± 23 
β-Endorphin 8.4 ± 4.9 64 ± 7 97 ± 2 4.3 ± 1.0 111 ± 27 83 ± 3 
  MOR-1C MOR-1D 
  Ki EC50 % max Ki EC50 % max 
DAMGO 0.9 ± 0.2 62 ± 4 100 0.8 ± 0.2 62 ± 6 100 
Morphine 2.7 ± 0.8 23 ± 5 75 ± 4 1.6 ± 0.2 82 ± 34 99 ± 3 
M6G 4.5 ± 1.8 51 ± 9 63 ± 7 4.8 ± 0.9 93 ± 32 95 ± 1 
Methadone 0.5 ± 0.1 57 ± 26 98 ± 5 1.4 ± 0.1 22 ± 1 102 ± 4 
Fentanyl 1.2 ± 0.4 37 ± 17 86 ± 24 3.3 ± 1.5 49 ± 15 96 ± 1 
β-Endorphin 5.8 ± 0.5 123 ± 19 44 ± 3 1.7 ± 0.5 73 ± 8 105 ± 6 
  MOR-1E 
     Ki EC50 % max 
   DAMGO 0.6 ± 0.2 48 ± 4 100 
   Morphine 2.4 ± 0.6 41 ± 13 116 ± 4 
   M6G 5.6 ± 0.9 123 ± 87 90 ± 6 
   Methadone 0.7 ± 0.3 25 ± 2 93 ± 5 
   Fentanyl 1.2 ± 0.5 37 ± 16 90 ± 3 
   β-Endorphin 4.9 ± 1.2 113 ± 25 130 ± 3 
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The potency (EC50) of the drugs also varied among the clones with no 
correlation to [35S]GTPγS binding and their binding affinity. DAMGO 
showed a 3 fold greater affinity in binding assays than morphine in 
MOR-1, but stimulated [35S]GTPγS binding with a potency 3 fold lower 
than morphine in comparison. The most intriguing observation is that 
the relative efficacy of the drugs to each other varied from one variant 
to the other. In MOR-1, methadone stimulation was much lower than 
fentanyl, whereas in MOR-1C cells, methadone was far more 
efficacious than fentanyl. 
 
To further add to the complexity of the signaling, the ability of these 
agonists to activate G proteins does not directly correlate with their 
ability to induce phosphorylation of the receptor, recruit β-arrestin 
and ultimately internalization. The amino acid differences in the C-
terminal tail also lead to differences in potential phosphorylation sites 
among these variants. These differences have been shown to lead to 
significant implications in receptor pharmacology following agonist 
binding. The C-terminal tail is believed to be involved in recruiting 
intracellular proteins to the receptor signalosome, altering signaling 
and trafficking.  
 
Signaling through β-arrestins is common to all GPCRs, however, the 
fate of the receptor- β-arrestin complex differs. β-arrestin signaling is 
mediated through a cluster of GRK-phosphorylated serine residues in 
the receptor carboxy terminal, which affects its ability to form a stable 
complex with β- arrestin (Schulz et al., 2004, Oakley et al., 2001). 
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Morphine bound receptor has low affinity for arrestins and undergoes 
limited receptor internalization in comparison to DAMGO (Groer et al., 
2011; Haberstock-Debic et al., 2003).  
 
The C-terminal splice variants differ in their agonist-selective 
membrane trafficking. Koch et al., have shown that MOR-1 and MOR-
1C stably expressed in HEK cells exhibited phosphorylation, 
internalization and down-regulation in the presence of the mu agonist, 
DAMGO, but not in response to morphine. In contrast, MOR-1D and 
MOR-1E exhibited robust phosphorylation, internalization and down-
regulation in response to both DAMGO and morphine. In addition, all 
the variants showed a similar desensitization pattern, measured 
during an 8-hour exposure to drug, and resensitization pattern, during 
a 50 minute drug withdrawal, in response to DAMGO. However, in 
response to morphine, MOR-1 and MOR-1C showed a faster 
desensitization and no resensitization as compared with MOR-1D and 
MOR-1E (Koch et al., 2001). Since phosphorylation and internalization 
of the receptor has been correlated with β-arrestin binding, these 
studies lay the ground for possible differences in arrestin recruitment 
pattern among the C-terminal splice variants. 
 
In another study from our lab, we observed differences in the 
internalization pattern of the MOR-1 and MOR-1C variants in an in-
vivo mouse model. The mice were treated with intracerebroventricular 
(i.c.v) DAMGO or Morphine. The internalization pattern was observed 
using brain slices treated with antibody against amino acids 410-430 
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in the murine MOR-1C or against amino acids 384-398 for MOR-1 
immunoreactivity. It was observed that MOR-1C-like immunoreactivity 
was observed in the endosomes in the cytoplasm, following both 
DAMGO and morphine treatment. In contrast, DAMGO and not 
morphine, internalized MOR-1-like immunoreactivity (Abbadie et al., 
2001).   
 
N-terminal splice variants 
 
The N-terminal splice variants were first identified by Pan et al in 
2001, where they demonstrated the retention of M6G and heroin 
analgesia in Pintar’s exon 1 knockout animal. The N-terminal variants 
are associated with the exon 11, which is an exon located 30kb 
upstream of exon 1 and contains an independent promoter region. A 
subset of the N-terminal variants skip exon 1 completely and lead to 
the formation of a truncated receptor with only 6TMs and lacking the 
first TM domain. Despite the truncation, these 6TM variants are 
expressed in a region-specific manner throughout the brain and spinal 
cord, albeit at lower levels relative to the full length MOR-1 (Abbadie et 
al., 2004; Ying-Xian Pan et al., 2001). 
 
There was an initial contention that this truncated form of the receptor 
was unlikely to be functionally active as it did not share the 7TM 
architecture with the other GPCRs. However, the generation of the 
MOR exon 11 knockout animal confirmed the physiological relevance 
of these 6TM variants. The exon 11 knockout animal retained most of 
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the full length MOR variants, except the ones requiring exon 11 as well 
as exon 1. As expected, these animals showed a slight 20% reduction 
in the [3H]-DAMGO sites as observed by the Bmax. Both,  morphine 
and methadone, retained their full efficacy in these animals without 
significant loss of analgesic potency. However, mu agonists like, 
heroin, fentanyl and M6G showed a significant right-shift in their 
analgesic potency. This highlighted the importance of the exon 11-
associated splice variants in the action of these drugs.  
 
Taken together with the results from antisense mapping and reciprocal 
MOR exon 1 knockout animal from Pintar’s group which expresses 
only truncated 6TM, the evidence overwhelmingly supports a model 
M6G and heroin act not only at the traditional mu receptors which 
mediate morphine’s effects, but also a pharmacologically and 
genetically distinct population of receptors involving truncated 6TM 
receptors. 
 
Phosphorylation sites at the µ-OR 
 
Like any other GPCR, the C-tail of µ-OR gets phosphorylated after 
receptor binding and is involved in downstream signal transduction. 
The early mechanistic studies on receptor phosphorylation were done 
in 1996 that showed that phosphorylation of µ-OR is mediated via 
GRKs and not PKC (Zhang et al., 1996). The ability of the opioid ligand 
to induce phosphorylation is correlated to its efficacy. Full agonists 
such as DAMGO, etorphine induce high MOR-1 phosphorylation as  
 37 
 
against morphine. Arden et al. reported that morphine-receptor 
complex is a poor GRK substrate and therefore, induces lower levels of 
receptor phosphorylation in HEK293 cells (Arden et al., 1995). The 
morphine-induced receptor phosphorylation is through a cAMP-
dependent protein kinase (PKA) mechanism whereas DAMGO-induced 
Figure 7 Predicted phosphorylation sites in the C-terminal Splice Variants of 
OPRM-1. Mouse, rat, and human c-terminal splice variant amino acid 
sequences are shown with symbols indicating predicted phosphorylation 
sites. Given the importance of phosphorylation in recruitment of b-arrestin, 
these differences are likely to have significant consequences on G- protein 
independent signaling and agonist bias. Reproduced from (Ying-Xian Pan, 
2005). 
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phosphorylation is GRK dependent (Chakrabarti et al., 1998). 
Consequently, overexpressing GRK2 in HEK cells lead to high levels of 
receptor phosphorylation (Zhang et al., 1998). In CHO cells, however, 
Yu and colleagues reported that morphine was able to induce µ-OR 
phosphorylation without GRK overexpression (Yu et al., 1997). These 
findings show that one of the major caveats in trying to understand 
the MOR system is that the agonist induced phosphorylation as 
observed in cell models suffers from a system bias and is dependent 
on the levels of specific protein kinases present in the cellular system.  
 
Initial experiments with deletion analyses were used to identify amino 
acid residues that are phosphorylated in MOR-1. Residues like Ser363 
present in the C-tail showed basal phosphorylation even in the 
absence of agonist. Agonist induced the phosphorylation of 2 amino 
acid residues in the C-tail, Thr370 and Ser375 (Lau et al., 2011, 
Moulédous et al., 2015). Ser375 phosphorylation was shown to be 
much faster than Thr370 phosphorylation. The mutation of Ser375 to 
Ala reduced the rate and extent of receptor internalization, whereas 
mutation of Ser363 and Thr370 to Ala accelerated MOR-1 
internalization kinetics (El Kouhen et al., 2001). Ser373, Thr370 and 
Ser375 lie in the exon 3 region and are all sites present in the 
conserved portion of C-tail. Additionaly, there is a Thr394 site that lies 
in the exon 4 region. Mutation of the Thr394 site to Ala in rMOR 
expressed in CHO cells results in the blunting of the agonist induced 
desensitization response (Pak et al., 1997). This could potentially link 
it to the β-arrestin mediated response. Deng et al. have also reported 
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GRK mediated Thr394 phosphorylation in the presence of agonists 
(Deng et al., 2000). However, other studies in HEK cells haven’t been 
able to demonstrate phosphorylation of the Thr394 site. Some studies 
have also reported the phosphorylation of Tyr residues in addition to 
Ser/Thr sites but the results have been controversial. 
 
Opioid receptor endocytosis is mediated by receptor phosphorylation 
and β-arrestin recruitment through the dynamin-dependent clathrin-
coated pits pathway. β-arrestin recruitment as well as internalization 
of the receptor have been shown to be ligand dependent event. A 
number of studies have shown that agonist directed differences in β-
arrestin2 recruitment are a function of the agonist’s ability to 
phosphorylate µ-OR. For example, the DAMGO stimulated receptor 
shows higher levels of phosphorylation, β-arrestin recruitment as well 
as internalization in comparison to morphine (Bohn et al., 2004). 
Etorphine but not morphine is able to induce receptor endocytosis 
(Keith et al., 1996).  
 
Interestingly though, it has been established that opioid receptor 
phosphorylation is not a prerequisite for receptor desensitization. Law 
and colleagues demonstrated that the time course of receptor 
phosphorylation is quite rapid in comparison receptor desensitization, 
as measured by adenylyl cyclase inhibition (Law et al., 2000). In 
addition, increasing the level of GRK expression increased the level of 
receptor phosphorylation but had no effect on the rate of receptor 
desensitization (El Kouhen et al., 1999, 2000; Law et al., 2000).  
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Crystal Structure 
 
More recently, the crystal structure of µ-OR was solved in the presence 
of an antagonist. The authors used T4 lysozyme and the truncation of 
the N and C termini to facilitate crystallization of the receptor. It was 
confirmed that all opioid receptors belong to the class A rhodopsin-like 
subfamily of G protein-coupled receptors (GPCRs) with a common 7TM 
helical architecture. The crystal structure of MOR-1 was initially 
solved using the selective µ-OR antagonist β-FNA. The binding pocket 
of MOR-1 was exposed to the extracellular surface. The ligand 
covalently attached to the Lys233 side chain and made contact with 
TM 3, 4, 6 and 7. MOR-1 homodimerized through an association 
between TM1, TM2, and helix 8 located on the intracellular C terminus 
(Manglik et al., 2012).  
 
Since then, the crystal structure of MOR-1 has also been solved in the 
agonist conformation. The receptor was bound by the morphinan 
BU72 and was stabilized in the agonist conformation using 
nanobodies (Huang et al., 2015). The nanobody created recognized 
MOR-1 bound to the selective agonist dmt-DALDA. As observed with 
the β-adrenergic, G protein binding was crucial for stabilizing MOR-1 
in its agonist conformation. Interestingly, in comparison to the 
antagonist state, the agonist conformation of the receptor revealed no 
sodium ion, due to a rearrangement of the sodium binding site. This is 
consistent with previous findings that reflect that the sodium ion aids 
the allosteric stabilization of the inactive state of the receptor (Pert et 
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al., 1973). However, as with the previous study by Manglik et al., the 
receptor was truncated as the N terminus to facilitate crystallization. 
Therefore, the physiological relevance of these studies is ambiguous. 
 
Biased Agonism 
 
The classical idea of GPCR function relayed a two-state model where a 
receptor can exist in either an active or an inactive state. The drug 
action was described as a function of its affinity, potency and efficacy, 
where affinity is defined as the ability of the ligand to interact with the 
receptor as measured by a Ki value. Efficacy (Emax) is defined as the 
ability of the bound ligand to activate the receptor and produce a 
measurable response in the system and potency (EC50) refers to the 
amount of drug required to achieve the required biological response. 
More recent studies in GPCRs, however, support the idea of more than 
one active state or conformation of the receptor (Swaminath et al., 
2004; Bokoch et al., 2010; Kahsai et al., 2011). The new evidence 
suggests that different ligands may be better at stabilizing one active 
state rather than another. This also sets forward the idea that the 
efficacies and potencies of the drug for these different active 
conformations of the receptors might vary and are not conserved 
among signaling pathways.  
 
Biased agonism or functional selectivity refers to the ability of the drug 
to activate a selective cell signaling pathway yet show very little 
efficacy in activating another pathway, in a way that cannot be 
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explained by traditional models of receptor theory. Consequently, it 
has become an important potential drug property, as it allows the 
identification and development of ligands that may be better able to 
induce the therapeutic effects of the receptor while minimizing the 
adverse effects of drug treatment. Several recent studies provide 
examples of therapeutic applications of biased agonism at several 
different GPCRs, like, the parathyroid hormone receptors (Gesty-
Palmer et al., 2009), GPR109A niacin receptor 2 (Walters et al., 2009), 
angiotensin II type 1 receptors (Zimmerman et al., 2012) as well as the 
MOR (DeWire et al., 2013). 
 
Biased Agonism at µ-OR 
 
Recent advances in the field allow for measuring multiple signaling 
outputs following activation of a receptor by a ligand, enabling the 
detection of ligand bias. There is an extensive body of work in the field 
that demonstrates agonist-determined differences in MOR-1 
responsiveness to key signaling pathways, like the activation of G 
protein and specific Gα subunits, regulation by kinases and β-
arrestins, as well as receptor internalization and desensitization.  
 
G protein Coupling 
 
Opioid receptors can couple to different inhibitory Gα subunits, like 
the Gαi and Gαo. However, the agonist and the cellular system dictate 
the specific subunit that a ligand couples to. Massotte and colleagues 
examined the coupling efficiencies of agonists like DAMGO, morphine 
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and buprenorphine. They reported that in HEK293 cells, DAMGO fully 
activates Gαi1 and only partially activates Gαi2. Morphine stimulated 
both subunits and behaved as a partial agonist at both Gαi1 and Gαi2. 
Interestingly, Buprenorphine, which is a more potent analgesic than 
both DAMGO and Morphine acted as a partial agonist at both 
subunits (Massotte et al., 2002; Raehal et al., 2011). Another study 
compared DAMGO with other endogenous peptides like, 
Endomorphin-1, Endomorphin-2 and β-endorphin and showed that 
they are all equally efficient at recruiting Gαi1 and GαoA. However, 
fentanyl, methadone, morphine and buprenorphine were partial 
agonists for both the subunits (Saidak et al., 2006). 
 
Morphine and M6G, both agonists at the mu receptor, exhibit different 
signaling and analgesic profiles. M6G is 100 fold more potent analgesic 
than morphine. However, in binding assays, M6G labels the mu 
receptor less potently than morphine. Antisense studies have shown 
that an antisense probe targeting Gαi2 blocks morphine analgesia but 
is inactive against M6G analgesia. Conversely, antisense blocking of 
Gαi1 inhibits M6G analgesia without affecting morphine analgesia 
(Standifer et al., 1996). Although, it should be noted that the loss of 
function observed in these experiments does not necessarily imply a 
physical association of the specific Gα subunit to the receptor. It could 
be a result of an interruption anywhere along the response pathway. 
Studies have also shown that agonists induce differential G protein 
activation during short-term and long-term drug administration.  
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In rats, chronic morphine treatment results in a switch from the 
inhibitory Gαi/o coupling to Gαs coupling in the striatum, spinal cord 
and periaqueductal gray (Chakrabarti et al., 2005). This indicates that 
the different interacting receptor/Gα combinations may not be 
equivalent in terms of signaling efficiency and some of these 
combinations might better relay the structural changes induced by a 
given agonist. 
 
Receptor Phosphorylation 
 
Agonist binding induces recruitment of several protein kinases to the 
receptor that phosphorylate specific serine, threonine and tyrosine 
residues. However, the extent of receptor phosphorylation as well as 
the sites phosphorylated is ligand dependent. Using 32P labeling in 
CHO-MOR-1, it has been shown that agonists like DAMGO, etorphine 
and methadone induce robust phosphorylation in comparison to 
morphine and buprenorphine (Yu et al., 1997). These findings have 
also been validated in HEK cell line using hemaglutinin-tagged (HA) 
receptor (Zhang et al., 1998; Koch et al., 2001; Schulz et al., 2004) 
 
Koch and colleagues explored the differences in receptor 
phosphorylation among the C-terminal splice variants of the receptor, 
mMOR-1C, mMOR-1D and mMOR-1E in HEK293 cells. It was 
observed that MOR-1C, like MOR-1, showed higher levels of receptor 
phosphorylation in response to DAMGO in comparison to morphine. 
However, the agonist specific differences were obliterated in the 
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mMOR-1D and mMOR-1E variants and both DAMGO and morphine 
induced similar levels of receptor phosphorylation (Koch et al., 2001). 
 
Recruitment of β-arrestins 
 
β-arrestin recruitment has become one of the more popular segment 
within biased agonism at the MOR. β-Arrestin 2 knockout mice have 
enhanced and prolonged morphine analgesia with reduced morphine 
tolerance, respiratory depression and constipation (Bohn et al., 1999; 
Raehal et al., 2005). Several studies have connected β-arrestin 
recruitment to the MOR side effects and so there is a huge effort in the 
field to develop agonists that are biased against β-arrestin recruitment 
(DeWire et al., 2013; Van der Westhuizen et al., 2014). Several assays 
like the PathHunter (DiscoverX), which uses enzyme fragment 
complementation to quantitate β-arrestin2 recruitment, as well as 
bioluminescence resonance energy transfer (BRET) and fluorescence 
resonance energy transfer (FRET) assay are being rapidly used.  
 
Agonists like morphine and heroin have been shown to be weak β-
arrestin recruiters in comparison to DAMGO and etorphine (Zhang et 
al., 1998; Whistler et al., 1998; Bohn et al., 2004). Another study also 
confirmed that Met-Enkephalin, etorphine, DAMGO and fentanyl 
induced robust β-arrestin recruitment in comparison to morphine, 
oxycodone and buprenorphine (McPherson et al., 2010; Molinari et al., 
2010).  
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Bohn and colleagues have developed a novel G protein biased agonist 
called herkinorin. Herkinorin has been demonstrated to be as 
efficacious as DAMGO at G protein coupling, ERK1/2 
phosphorylation, cAMP inhibition in HEK293 as well as CHO cell lines 
expressing MOR-1. However, unlike DAMGO, herkinorin does not 
recruit β-arrestins (Harding et al., 2005; Groer et al., 2007; Xu et al., 
2007). TRV130, is another G protein biased agonist that has been 
developed by Violin and colleagues (DeWire et al., 2013; Soergel et al., 
2014; Viscusi et al., 2016).   
 
Quantifying biased agonism 
 
When trying to determine possible ligand bias, the methods for 
quantifying ligand bias are crucial. More so, because bias is usually 
not absolute and it is quite rare for an agonist at GPCR to fully 
activate one pathway and is completely inactive at another. As a 
result, the field is constantly evolving and several different approaches 
have been developed to quantify bias (Rajagopal et al., 2011; Kenakin 
et al., 2012, 2013). It is also important to consider that the observed 
response by a ligand at a signaling pathway is not solely determined 
by its affinity and efficacy. Rather, the observed response is a function 
of the differing coupling efficiencies of the signaling pathways referred 
to as system bias, as well as the differing conditions and sensitivities 
of the detection method called the observation bias. 
 
 
 47 
Equimolar comparison:  
 
The equimolar approach of quantifying bias was first proposed by 
Christopolous in 2010 (Gregory et al., 2010). It is a qualitative 
approach in which the data for a single ligand is collected in two 
different assays, such as a G protein assay and a β-arrestin assay. The 
responses of the two assays are then plotted against each other and 
the shape of the curve is used as a direct comparison of signaling 
through the two pathways. The concentration-response data are 
plotted against each other yielding a hyperbolic curve. One caveat with 
using just a hyperbolic curve is that it would suggest bias towards the 
assay that has a higher sensitivity. In order to avoid such a problem, 
the shape of the equimolar curve is normalized and compared to that 
of a reference balanced ligand. The bias of the test ligand is 
determined with respect to the balanced ligand.  
 
Equiactive comparison: 
 
Historically, it has been thought that all agonists activate the receptor 
by stabilizing a single active conformation of the receptor and that it is 
only the strength of the signal that varies and determines the observed 
efficacy. This model can also be referred to as the ‘agonist potency 
ratio’. Potency of an agonist is the agonist concentration that produces 
50% of the maximal response. This comparison can be performed 
using a formula for intrinsic relative activities proposed by Ehlert in 
2008.  
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The bias factor (!) is calculated as the logarithm of the ratio of 
intrinsic relative activities for a ligand at two different assays 
compared to a reference ligand where P1 and P2 denote the two 
signaling pathways 1 and 2, respectively (Figueroa et al., 2009).  
 
In order for any of these bias quantifications to have any value in the 
drug discovery process, it is important that these ratios or calculations 
are valid in a system other than the test system i.e a monotonic 
relationship between receptor stimulation and cellular response. 
However, when this assumption is not valid, agonist potency ratios 
developed in one reference system become less useful for drug 
discovery.  
 
Operational Model: 
 
This approach is based on classic pharmacological model proposed by 
Black and Leff in 1983 and accounts for receptor reserve and shifts in 
agonist concentration-response curves. Until now, ligand bias was 
quantified by comparing the maximal effects (Emax) and potencies 
(EC50) of ligands in different signaling pathways. Although effective, 
these parameters don’t account for differences in receptor reserve and 
signal amplification in different assays. Specifically assays with 
significant amplification, can lead to a false interpretation of bias 
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because both full and partial agonists can reach the same maximal 
response (Rajagopal et al., 2011).  
 
We chose to use the operational model of Black and Leff to quantify 
the effective signaling by receptors. To compare the relative activity of 
agonists in the two pathways and identify the bias, we generated 
concentration response curve for each signaling pathway. In the 
operational model, the response of the system to ligand stimulation is 
based on receptor occupancy alone. τ is the coupling efficiency 
between the agonist/receptor complex and the downstream signaling 
partners. ; = <=>=3 +	 ;@=A − <=>=3 τD A DτD A D +	( A + Ka)D  
 
The caveat with using the operational model is that it assumes that 
the agonist-receptor complex has an identical affinity for separate 
signaling pathways. As proposed by Kenakin et al., instead of 
assuming an identical Ka value, the operational model can be modified 
to determine the transduction ratios (τ/Ka) of the agonists. (Kenakin et 
al., 2012; Van der Westhuizen et al., 2013; White et al., 2014).  
 ; = <=>=3 +	 ;@=A − <=>=3 ( HIJ)D A D( HIJ)D A D +	([L]IJ)D + 1)D  
 
τ incorporates agonist coupling, efficacy and receptor density in the 
system and Ka is the reciprocal of the conditional affinity of the 
agonist in the functional system. It has been shown that transduction 
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coefficients remain constant over large changes in receptor density 
(Kenakin et al., 2012) 
 O log PQ= = 	 log PQ= 345=RS −	 log PQ= T89 
 OO log UV*  = O log UV* W=XℎZ=[	1 −	 log UV* W=XℎZ=[	2 
 
 
Bias Factor = 10ΔΔlog( ]^_)D 
 
The log(τ/Ka) of each test ligand can then compared with the log(τ/Ka) 
of a reference ligand, like DAMGO, for both G protein activation and 
arrestin recruitment. It is ideal to use a reference ligand that has very 
similar EC50 value for both the G protein and arrestin pathways and 
displays full efficacy at both pathways. Ligand bias is quantified by 
comparing the relative activity of an agonist in one assay to the relative 
activity in another assay, using the same reference ligand. This 
method reduces to the observation or the system bias (Kenakin et al., 
2013). Transduction coefficients are useful in comparing the relative 
signaling of ligands, but can be problematic when trying to measure 
the efficacy of agonists that produce maximal or no effects in a given 
signaling pathway, like Buprenorphine (Rajagopal, 2013). 
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Chapter II - Materials and Methods 
 
In-Vitro Assays  
 
Competition Binding Assay 
 
Membranes from cells were prepared by manually lifting cells from the 
culture plates with a rubber septum into PBS. Cells were pelleted at 
1,200g for 10 min and the pellet was resuspended in 20 volumes of 
TRIS buffer (50 mM; pH 7.4 at 25°C), potassium EDTA (1mM), sodium 
chloride (100mM), and phenylmethylsulfo- nylfluoride (10M). The 
homogenate was then incubated at 25°C for 15 min and centrifuged at 
14,000rpm for 30 min. The resulting pellet was resuspended in 0.32M 
sucrose, homogenized, and aliquots were quick-frozen on dry ice. The 
membranes were stored at –70°C and retained their binding for at 
least 6 weeks. 
 
Binding Studies: [125I]-IBNtxA binding assays were carried out in 
Chinese Hamster Ovary (CHO) cells stably expressing mMOR-1 
receptors. Cell membrane homogenates were prepared as previously 
described at a concentration of 3 - 10µg protein in a volume of 0.5 - 
1ml of homogenate. Nonspecific binding was determined in the 
presence of levallorphan (1µM) and was subtracted from the total 
binding counts per million (cpm) to yield specific binding. Specific 
binding is reported. Binding was carried out for 90 min (equilibrium) 
at 25°C using 0.5 to 1ml of homogenate. Glass fiber filters were soaked 
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in 0.5% polyethyleneimine for at least 15 minutes prior to filtration to 
minimize nonspecific binding to the filters. KD, Bmax, and Ki values 
were calculated by nonlinear regression analysis (GraphPad Prism, 
San Diego, CA). Data is reported as mean and S.E.M. of at least 3 
independent replicates.  
 
[35S]GTPγS Binding Assay 
 
Stimulation of [35S]GTPγS binding: [35S]GTPγS assays were performed 
based upon published methods (Selley et al., 1998; Bolan et al., 2004; 
Pan et al., 2005). Membrane homogenates from CHO cells stably 
transfected with mMOR or its splice variants (200 µg protein) were 
incubated for 1 hour at 30°C with the indicated drug, [35S]GTPγS 
(0.05nM) and GDP (60µM) in a final volume of 1ml assay buffer. The 
assay buffer contained Tris HCl (50 mM; pH 7.4 at 37°C), MgCl2 
(3mM), EGTA (0.2mM), NaCl (100mM), and a protease inhibitor 
cocktail (leupeptin, bestatin, aprotinin, and pepstatin). Nonspecific 
binding was assessed by the addition of 100µM cold GTPγS Binding 
was terminated by vacuum filtration through Whatman GF/C glass 
fiber filters which were rinsed 3 x 3ml with cold Tris HCl. Filters were 
cut out and 3ml of scintillation fluor (Liquiscint, National Diagonistics, 
Atlanta, GA) was added to each tube and incubated at room 
temperature for at least 3 hours before being counted on a Packard 
Tri-Carb TR-2900 liquid scintillation counter.  
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DiscoverX PathHunter assay 
 
The PathHunter enzyme complementation assay was performed 
according to the manufacturer’s protocol. Chinese Hamster Ovary 
(CHO) cells expressing MOR-1 tagged with a complementary β-gal 
donor fragment at the C-terminal region and β-arrestin-2 tagged with 
a complementary β-gal activator (EA) fragment were obtained from 
DiscoverX. When the receptor is activated, the β-arrestin-2 
translocates to the active receptor and forms a functional enzyme. The 
cells were maintained in F-12 media with 10% fetal calf serum + 
Penicillin + Streptavidin. The media was supplemented with 800µg 
G418 and 300µg Hygromycin for cell selection. For the arrestin assay, 
the cells were plated at 2500 cells/ well in a 384 well plate. The next 
day, the cells were treated with the agonist compound for 90min at 
37°C and β-arrestin-2 recruitment was measured using the 
PathHunter detection kit and read for chemiluminiscence on a Tecan 
plate reader. 
 
Phospho-ERK1/2 Western 
 
HEK-293 cells stably expressing a N-terminus hemagglutinin (HA) -
tagged mouse MOR-1 or MOR-1O were assessed for agonist-induced 
ERK1/2 phosphorylation. Cells were serum-starved at 37°C under 5% 
CO2 for 30 min before drug treatment. For these assays, the cells were 
treated with PBS, 1µM DAMGO, Buprenorphine and Fentanyl. Cells 
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were stimulated for 5 minutes in the presence of agonists, and cell 
lysates were prepared on ice in lysis buffer. The Lysis buffer 
constituted 20mM Tris-HCl, pH 7.5, 150mM NaCl, 2mM EDTA, 0.1% 
SDS, 1% NP-40, 0.25% deoxycholate, 1mM sodium orthovanadate, 
1mM PMSF, 1mM NaF, with Complete Mini, EDTA-free protease 
inhibitor cocktail tablet (Roche Diagnostics, Indianapolis, IN). Protein 
levels were determined with the use of the detergent-compatible 
protein assay system (Bio-Rad Laboratories, Hercules, CA), and 20 g of 
protein was loaded per lane on 10% Bis-Tris gels for gel 
electrophoresis (Bio-Rad Laboratories or Invitrogen, Carlsbad, CA). 
Proteins were transferred to polyvinylidene fluoride (PVDF) membranes 
(Immobilon P; Millipore, Billerica, MA) and blocked in 5% milk for 1 
hour at room temperature. After blocking, the blots were incubated 
with antibody for total or phosphorylated ERK1/2 (anti-phospho 
ERK1/2 antibody 1:1,500 dilution, #4370, Cell Signaling or an anti-
total ERK1/2 antibody 1:1,000 dilution, #4695, Cell Signaling) 
overnight at 4°C. Total ERK1/2 levels were used to normalize the 
overall phosphorylation of ERK1/2 between samples. 
Chemiluminescence was detected and quantified using the BioRad 
imaging device and Prism software (GraphPad Software, Inc., San 
Diego, CA).  
 
Bias Factor Calculation 
 
We chose to use the operational model of Black and Leff to quantify 
the effective signaling by receptors. To compare the relative activity of 
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agonists in the two pathways and identify the bias, we generated 
concentration response curve for each signaling pathway. In the 
operational model, the response of the system to ligand stimulation is 
based on receptor occupancy alone. τ is the coupling efficiency 
between the agonist/receptor complex and the downstream signaling 
partners. ; = <=>=3 +	 ;@=A − <=>=3 τD A DτD A D +	( A + Ka)D  
 
The caveat with using the operational model is that it assumes that 
the agonist-receptor complex has an identical affinity for separate 
signaling pathways. As proposed by Kenakin et al., instead of 
assuming an identical Ka value, the operational model can be modified 
to determine the transduction ratios (τ/Ka) of the agonists. (Kenakin et 
al., 2012; Van der Westhuizen et al., 2013; White et al., 2014).  
 ; = <=>=3 +	 ;@=A − <=>=3 ( HIJ)D A D( HIJ)D A D +	([L]IJ)D + 1)D  
 
τ incorporates agonist coupling, efficacy and receptor density in the 
system and Ka is the reciprocal of the conditional affinity of the 
agonist in the functional system. It has been shown that transduction 
coefficients remain constant over large changes in receptor density 
(Kenakin et al., 2012) 
 O log PQ= = 	 log PQ= 345=RS −	 log PQ= T89 
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OO log UV*  = O log UV* W=XℎZ=[	1 −	 log UV* W=XℎZ=[	2 
 
Bias Factor = 10ΔΔlog( ]^_)D 
 
The log(τ/Ka) of each test ligand can then compared with the log(τ/Ka) 
of a reference ligand, like DAMGO, for both G protein activation and 
arrestin recruitment. It is ideal to use a reference ligand that has very 
similar EC50 value for both the G protein and arrestin pathways and 
displays full efficacy at both pathways. Ligand bias is quantified by 
comparing the relative activity of an agonist in one assay to the relative 
activity in another assay, using the same reference ligand. This 
method reduces to the observation or the system bias (Kenakin et al., 
2013). Transduction coefficients are useful in comparing the relative 
signaling of ligands, but can be problematic when trying to measure 
the efficacy of agonists that produce maximal or no effects in a given 
signaling pathway, like Buprenorphine (Rajagopal, 2013). 
 
In-Vivo Assays 
 
Morphine analgesia 
 
A radiant-heat tail-flick assay was used to test for analgesia. The 
animals were tested 30 min post-injection with a maximal latency of 
10 seconds to minimize tissue damage. The results are reported as the 
percentage of maximum possible effect (%MPE), which is calculated as 
[(latency after drug baseline)/(10 – baseline latency)*100]. For the dose 
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response studies, animals were treated with 1, 2, 4, 8, 16 or 32 mg/kg 
dose of morphine. ED50 values were determined using nonlinear 
regression analysis (GraphPad Prism 6).  
 
Morphine tolerance and physical dependence studies 
 
Tolerance in the targeted mice on B6 background and CD-1 mice was 
induced by twice-daily injections with morphine (10 mg/kg, s.c.) for 5 
days. Tolerance in the targeted mice on 129 background was induced 
by twice-daily injections with escalating doses of morphine (s.c., day 1, 
10 mg/kg; days 2 & 3, 20 mg/kg; days 4 & 5, 40 mg/kg). Morphine 
analgesia was examined on Days 1, 3 and 5. Morphine dependence 
was determined on day 5 with naloxone (s.c., 1 mg/kg for mice on B6 
background and 30 mg/kg for mice on 129 backgrounds and CD-1 
mice) injection 3 hours after the last morphine treatment to precipitate 
withdrawal. The number of jumps within 15 min immediately following 
the naloxone injection was used for the measurement of withdrawal. 
 
Statistical analyses 
 
Statistical analysis was carried out using GraphPad Prism 6. A one-
way ANOVA with post hoc Bonferroni’s multiple comparisons test was 
used if more than two groups were compared, and a two-way ANOVA 
with post hoc Bonferroni’s multiple comparisons test was used if two 
independent variables were compared. Data are represented as the 
means ± SEM of at least three independent experiments. Statistical 
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significance was set at p < 0.05.  For the in-vivo experiements, all mice 
were randomized and assigned to groups. Some, but not all, 
experiments were performed under blinded conditions. 
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Chapter III - Results 
 
The opioid field and the quest for the ideal analgesics with limited side 
effects has accumulated decades of research and thousands of new 
opioid compounds. However, in spite of the substantial advances in 
the understanding of opioid receptor pharmacology, analgesics such 
as morphine, fentanyl, and oxycodone, that target the mu opioid 
receptor and exhibit the side effect profile - tolerance, dependence, 
constipation, respiratory depression, and euphoria resulting in abuse 
and addiction, remain the mainstays of pain management.  
 
The history of opioid pharmacology has revolved around discovering 
and exploiting receptor heterogeneity to maximize the desired 
therapeutic effects while minimizing off-target side effects. This began 
with first splitting opioid receptors into the different subclasses, mu, 
delta and kappa. And then evolved into understanding the different 
subtypes under these subclasses.  More and more studies have 
revealed the existence of homo- and heteromeric signaling complexes 
comprised of multiple GPCRs, which exhibit unique properties from 
their component receptors and may be specifically targeted by drugs 
(Gomes et al., 2004, 2013; Jordan & Devi, 1999; Yekkirala et al., 
2009). In this study, our approach has been to reconcile the 
pharmacologically defined opioid receptor subtypes with the extensive 
alternative splicing observed for the mu opioid receptor gene.  
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The Oprm gene has been mapped to be greater than 250 kb long and 
has at least 18 different exons (Pan et al., 2001). The gene shows 
extensive alternative splicing and more than 60 different splice 
variants have been identified. Specifically, the C-terminal splice 
variants sub-family of receptors consist of exons 1, 2 and 3 with 
alternative splicing downstream of exon 3 (Figure 8). Since these 
variants share the first 3 exons, they encode for all the 7 TM domains 
as well as a significant portion of the C-tail. As a result, these 
receptors have an identical binding pocket encoded by transmembrane 
2, 3, 5 and 7. They selectively label mu opioids in binding assays and 
are antagonized by mu opioid-selective antagonists. The only 
difference among these variants is at the tip of the C-tail (Rossi et al., 
1994, 1995a,b, 1996, 1997; Pasternak and Standifer, 1995; Schuller 
et al., 1999).  
 
Opioid receptors are known to couple to the inhibitory G proteins 
(Gi/Go) family in an agonist dependent manner (Childers, 1991; 
Standifer and Pasternak, 1997). However, the sensitivity profile of mu 
analgesics vary significantly, with Giα2 implicated in morphine 
analgesia and Giα1 involved in M6G analgesia (Standifer et al., 1996). 
Additional G protein α-subunits have also been implicated in opioid 
analgesia. This diversity of mu opioid receptors and the differing G 
proteins involved with mu opioid actions raises the question of 
whether or not the G protein interactions of some of these Oprm splice 
variants may differ due to structural differences at the tip of the C-
terminus. 
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Some of this has already been demonstrated. The C-terminal splice 
variants of µ-OR differ in their regional distribution, agonist induced G 
protein coupling (as measured by [35S]GTPγS binding), receptor 
phosphorylation, internalization and post-endocytic sorting. 
Functional differences among the variants have been demonstrated 
using [35S]GTPγS binding and adenylyl cyclase coupling. Zimprich et 
al. demonstrated that the functional coupling to adenylyl cyclase 
desensitizes at a slower rate in the mMOR-1B variant than in mMOR-
1. This is due to rapid resensitization and recycling of mMOR-1B to 
the plasma membrane (Koch et al., 1998). However, different mu 
Figure 8 Schematic showing the Oprm gene structure and the C-terminal 
splice variants. All of these variants contain exons 1, 2 and 3 with splicing 
downstream of exon 3. Exons are represented in boxes and are numbered 
based on when they were reported. Exons and introns are represented by 
boxes and horizontal lines, respectively. Translational start codons and 
termination codons are indicated by heavy vertical lines. 
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agonists differentially bias this receptor recycling process. DAMGO 
induced desensitization, measured as a decay of the opioid activated 
GIRK current, is much slower in mMOR-1B than in the mMOR-1 and 
mMOR-1A variants. However, all three splice variants undergo rapid 
desensitization in response to morphine (Oldfield et al., 2008). 
 
Our current approach has been to better understand how the 
differences at the C-terminus of the receptor affect its interaction with 
the downstream signaling pathways. This understanding of the 
downstream molecular targets would eventually help in optimizing and 
discovery better opioid analgesics. 
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Part I - C-terminal splice variants differentially regulate G protein 
pathways 
 
In the current study, we expanded the number of C-terminal variants 
and series of opioids to screen for the stimulation of [35S]GTPγS 
binding while simultaneously using a cell line that allowed for a 
comparison between the stimulation of the G protein and β-arrestin 
pathways. We used the cell lines developed for the DiscoverX 
PathHunter assay. These are CHO cells expressing the µ-OR tagged 
with a complementary β-gal donor fragment (called the prolink (PK) 
fragment) at the C-terminal region. The β-arrestin-2 is tagged with a 
complementary β-gal activator (EA) fragment. It is an enzyme 
complementation assay that leads to a functional β-gal formation upon 
agonist induced β-arrestin-2 recruitment to the receptor.  
 
We tested 6 C-terminal splice variants with varying C-terminal tails, 
mMOR-1-PK, mMOR-1A-PK, mMOR-1B1-PK, mMOR-1C-PK, mMOR-
1E-PK and mMOR-1O-PK, along with a control receptor MOR-TR-PK. 
The control receptor MOR-TR-PK has exons 1, 2, 3, with nothing 
downstream of exon 3. These C-terminal splice variants differ at the 
tip of the C-terminus with differences in length of the C-tail, specific 
amino acid residues at the tail, along with, conformation and potential 
phosphorylation sites at the C-tail. We attempted to study the effect of 
adding amino acids downstream of exon 3 in its ability to recruit G 
proteins.  
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The µ-OR clonal cell lines were selected based on expression level of 
the clone using [125I]-IBNtxA competition binding assay and saturation 
studies. We picked the clones with relatively high and similar 
expression levels across the 7 different constructs (Figure 9). 
 
We first wanted to confirm that these DiscoverX splice variants clones 
show similar affinities for a number of mu agonists, as previously 
published in Bolan et al., 2004. This would ensure that the extra PK 
fragment at the C-terminus of these variants was not interfering with 
drug interaction. We did competition binding assays with 2 DiscoverX 
clones, mMOR-1-PK and mMOR-1O-PK, which are the clones with the 
highest and lowest expression level and compared it with a regular 
mMOR-1 clone without the additional prolink fragment, also expressed 
in CHO cells. The DiscoverX constructs are indicated with a PK 
(prolink) to differentiate them from the non-modified receptor variant, 
mMOR-1 expressed in CHO cells. 
 
We observed that the addition of the prolink fragment at the C-
terminal tail of the receptor had no effect on the binding affinity of 
several mu agonists for the receptor. We saw this in both mMOR-1-PK 
and mMOR-1O-PK receptor variants (Figure 10, 11). Next, we chose to 
examine the functional differences among the C-terminal variants by 
measuring their ability to stimulate [35S]GTPγS binding. [35S]GTPγS 
binding is an in-vitro assay that serves an estimation of the agonist 
induced G protein coupling across the receptor variants. Since the  
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Figure 9 Saturation binding experiments represent the expression level of the 
receptor variants in the DiscoverX cell lines. 6 different C-terminal variants were 
characterized along with the control receptor MOR-TR-PK which is truncated 
after exon 3. Results are the mean ± S.E. of at least three independent 
experiments. 
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receptors in the DiscoverX cell lines have seemingly high expression 
levels, we first wanted to check if the endogenously expressed levels of 
G proteins in these cells lines might be rate limiting in [35S]GTPγS 
binding assay. The receptor in a [35S]GTPγS binding assay can interact 
with more than one G protein, therefore, a skewed receptor : G protein 
ratio could impact the ability of the receptor in activating G proteins. 
For this purpose, we used the DiscoverX cell line with the highest 
expression level, CHO-MOR-1-PK and compared its efficacy and 
potency in the [35S]GTPγS binding assay to the CHO-MOR-1 cell line 
(Figure 12). We noticed that even though the expression level of the 
clones had no significant impact on the potency (EC50) of the mu 
agonists, it does seem that the CHO-MOR-1 cell line is more effective 
(Emax - % basal stimulation) in the [35S]GTPγS binding assay. This 
difference could be a combined response to the difference in receptor 
expression level in the 2 clones as well as the signal amplification in 
the [35S]GTPγS binding assay. As a result, we have normalized all the 
Emax values to % DAMGO stimulation at the receptor variant to 
eliminate any inherent biases due to differences in receptor expression 
level. This allows us to carefully characterize the response of the drugs 
across the different variants while eliminating any system bias. 
 
 
  
 67 
  
  
Figure 10 Competition binding curves in engineered CHO cell lines stably expressing 
MOR-1 and MOR-1-PK receptor variants. The DiscoverX variant is represented by MOR-
1-PK. Competition binding curves was generated for 4 mu agonists, A. DAMGO, B. 
Fentanyl, C. b-Endorphin and D. Methadone. The Ki values were calculated on 
GraphPad Prism using non-linear regression analysis. The binding studies depict that 
the additonal prolink fragment at the C-terminus tail of the receptor has no significant 
effect on the affinity of the mu agonists for the receptor variant. Results are the mean ± 
S.E. of at least three independent experiments. 
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Figure 11 Competition binding curves in engineered CHO cell lines stably 
expressing MOR-1O and MOR-1O-PK receptor variants. The DiscoverX variant 
is represented by MOR-1O-PK. Competition binding curves was generated for 4 
mu agonists, A. DAMGO, B. Fentanyl, C. b-Endorphin and D. Methadone. The 
Ki values were calculated on GraphPad Prism using non-linear regression 
analysis. The binding studies depict that the additonal prolink fragment at the 
C-terminus tail of the receptor has no significant effect on the affinity of the mu 
agonists for the receptor variant. Results are the mean ± S.E. of at least three 
independent experiments. 
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Figure 12 [35S]GTPγS binding curves to observe the role of the difference in 
receptor expression level in these assays. We used the DiscoverX MOR-1-PK 
cell line with the highest receptor expression level and compared with CHO-
MOR-1 cell line. A comparison of the [35S]GTPγS binding curves were 
generated for 4 mu agonists, A. DAMGO, B. Fentanyl, C. Endomorphin1, D. 
Endomorphin2. The EC50 values were calculated on GraphPad Prism using 
non-linear regression analysis. Results are the mean ± S.E. of at least three 
independent experiments. 
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After optimizing the assay, we tested the 6 C-terminal variants, 
mMOR-1-PK, mMOR-1A-PK, mMOR-1B1-PK, mMOR-1C-PK, mMOR-
1E-PK and mMOR-1O-PK, along with the control variant mMOR-TR-
PK in their ability to stimulate [35S]GTPγS binding in response to 9 
different mu agonists.  The ability of the various mu opioids to 
stimulate [35S]GTPγS binding varied markedly. However, the 
differences among the splice variants and among the drugs in the 
stimulation of [35S]GTPγS followed no predictable pattern. Some 
opioids were as efficacious as full agonists in cells expressing one 
variant and then showed low efficacy as a partial agonist in another. 
We observed significant differences in both the potency and maximal 
stimulation of the drug across variants, with the most differences 
observed in the mMOR-1O variant.  
 
In response to DAMGO, the mMOR-1 (14nM) variant was more than 
10 fold potent in triggering the maximal effect (Emax) of the drug in 
comparison to mMOR-1C (217nM) and mMOR-1O (166nM). The Emax 
and EC50 values are shown in Table 5. We compared the response of 
the variants to the control truncated exon 3 receptor to understand 
how the addition of few or more amino acids at the tip of the C-
terminus affects the interaction of the receptor with other G proteins. 
Interestingly, the mMOR-TR response to β-endorphin was significantly 
right shifted while the other C-terminal variants with longer C-tails 
were significantly more potent in inducing the β-endorphin response 
(Figure 12). For example, with the addition of as few as 4 amino acids 
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in its C-tail, mMOR-1A was almost 20 fold more potent inducing the β-
endorphin response in comparison to the control receptor.  
 
The length of the C-tail, however, did not have a direct relationship 
with the efficacy of the drug. A longer C-tail does not always lead to 
better drug efficacy. For example, most of the C-terminal variants with 
their different C-tails show no marked differences in response to 
morphine except mMOR-1O. The mMOR-1O receptor was significantly 
less potent and effective in the [35S]GTPγS assay in comparison to the 
control receptor and mMOR-1. Similarly, in response to 
Endomorphin1, the mMOR-1 receptor was again significantly more 
potent than the mMOR-1O receptor in the [35S]GTPγS assay.  
 
Endomorphin2, another potent peptide agonist at the mu receptor, 
had differences in both maximal stimulation as well as potency of the 
drug. At the mMOR-1A receptor, Endomorphin2 receptor was a full 
agonist that stimulated the receptor response at 124% of DAMGO. 
However, it was a partial agonist with a maximal efficacy of only 66% 
of DAMGO at the mMOR-1O receptor. In addition to the difference in 
efficacy, the drug was also two fold more potent at the mMOR-1A 
receptor in comparison to the mMOR-1O receptor. This is interesting 
because the mMOR-1A C-tail has 4 additional amino acids 
downstream of exon 3, whereas, mMOR-1O has an even longer C-tail 
with 30 additional amino acids.  
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Both mMOR-1C and mMOR-1O receptor variants have exon 7 at the 
C-tail and overlap in 30 amino acids downstream of exon 3. In 
addition to exon 7, mMOR-1C also contains exons 8, 9 and an extra 
22 amino acids in the C-tail. In spite of the similarity in between these 
2 variants, mMOR-1C is much more effective (188% of DAMGO) than 
mMOR-1O (101% of DAMGO) in triggering the G protein pathway in 
response Methadone. Met-Enk-Arg-Phe, another peptide, had a very 
diverse signaling profile across the variants. The peptide was 
significantly more potent in some variants like, mMOR-1E (7nM), 
mMOR-1 (14nM) and mMOR-1A (13nM), in comparison to other 
variants like, mMOR-1C (71nM) and mMOR-1O (84nM).  
 
Although these assays do not provide sufficient evidence into why 
these C-terminal differences lead to differences in ability of the 
receptor to activate and signal through the G protein pathway, there 
can be a number of possibilities. As mentioned earlier, all of these C-
terminal variants share the 7TM domains and differ only in the amino 
acid sequence at the very tip of the C-terminus. One possible reason 
for the observed differences across receptor variants could be that 
these alternatively spliced sequences contain differential 
phosphorylation sites that influence their function. Secondly, the 
lengths of the spliced C-terminal tails vary markedly. Although, we 
didn’t find a directly proportional relationship between the length of 
the C-tail and the signaling from the receptor, we anticipate that the 
sequences and length of the alternatively spliced regions may modify 
the structure of the receptor and impact its ability to interact with 
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other protein complexes. Furthermore, it has been shown that in 
addition to the C-terminal tail, the third intracellular loop of the 
GPCRs is involved in G protein coupling, binding of calmodulin and 
arrestin. The differences in the C-tail across the receptor variants may 
influence their interaction and steric interference with the other 
regions of the receptor, and in specific, the third intracellular loop. The 
C-terminus has been implicated in the binding of arrestins and may be 
important in distinguishing between two classes of GPCRs (Oakley et 
al., 2000). 
 
One potential caveat and limitation with the interpretation of these 
results is that these findings are dependent on assay conditions and 
the cell line used. Mu opioid receptors have been shown to interact 
with the Gi/Go family of G protein subunits (Traynor et al., 2002). 
However, the CHO cells that we used in the [35S]GTPγS assay express 
all the G subunits implicated in opioid analgesia, with the exception of 
Gia1. Since the expression of this specific G protein differs between 
the cell line we used and endogenous expression in the brain, it is 
possible that the correlation of specific Ga subunit we are observing in 
our assays is different. We anticipate the differences to not be that 
significant as the GPCRs are known to recruit G proteins other than 
those they normally use depending on availability and expression, and 
the CHO cells used in our assays should still provide insights into the 
functional differences among the C-terminal variants (Shapira et al., 
2000).  
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Figure 13 [35S]GTPγS binding curves to compare the response of several mu 
agonists across the various C-terminal splice variants in the G protein assay.   
Left panel: variants mMOR-TR, mMOR-1, mMOR-1A and mMOR-1B 
Right panel: variants mMOR-TR, mMOR-1C, mMOR-1E, mMOR-1O 
A comparison of the [35S]GTPγS binding curves were generated for 3 mu 
agonists, A. and B. DAMGO, C. and D. Morphine, E. and F. b-Endorphin. 
The data was analyzed on GraphPad Prism using non-linear regression 
analysis. Results are the mean ± S.E. of at least three independent 
experiments. 
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Figure 14 [35S]GTPγS binding curves to compare the response of several mu 
agonists across the various C-terminal splice variants in the G protein assay.   
Left panel: variants mMOR-TR, mMOR-1, mMOR-1A and mMOR-1B 
Right panel: variants mMOR-TR, mMOR-1C, mMOR-1E, mMOR-1O 
A comparison of the [35S]GTPγS binding curves were generated for 3 mu 
agonists, A. and B. Endomorphin 1, C. and D. Endomorphin 2, E. and F. 
Met-Enk-Arg-Phe. The data was analyzed on GraphPad Prism using non-
linear regression analysis. Results are the mean ± S.E. of at least three 
independent experiments. 
  
Ba
sa
l
0
50
100
-10 -9 -8 -7 -6 -5
[Endomorphin 2, log M]
%
 D
A
M
G
O
 E
m
ax
MOR-TR
MOR-1C
MOR-1E
MOR-1O
Ba
sa
l
0
50
100
-10 -9 -8 -7 -6 -5
[Met-Enk-Arg-Phe, log M]
%
 D
A
M
G
O
 E
m
ax
MOR-TR
MOR-1C
MOR-1E
MOR-1O
Ba
sa
l
0
50
100
-10 -9 -8 -7 -6 -5
[Met-Enk-Arg-Phe, log M]
%
 D
A
M
G
O
 E
m
ax
MOR-TR
MOR-1
MOR-1A
MOR-1B
Ba
sa
l
0
50
100
-10 -9 -8 -7 -6 -5
[Endomorphin 2, log M]
%
 D
A
M
G
O
 E
m
ax
MOR-TR
MOR-1
MOR-1A
MOR-1B
Ba
sa
l
0
50
100
-10 -9 -8 -7 -6 -5
[Endomorphin 1, log M]
%
 D
A
M
G
O
 E
m
ax
MOR-TR
MOR-1C
MOR-1E
MOR-1O
Ba
sa
l
0
50
100
-10 -9 -8 -7 -6 -5
[Endomorphin 1, log M]
%
 D
A
M
G
O
 E
m
ax
MOR-TR
MOR-1
MOR-1A
MOR-1B
A B 
C D 
E F 
 76 
 
Figure 15 [35S]GTPγS binding curves to compare the response of several mu 
agonists across the various C-terminal splice variants in the G protein assay.   
Left panel: variants mMOR-TR, mMOR-1, mMOR-1A and mMOR-1B 
Right panel: variants mMOR-TR, mMOR-1C, mMOR-1E, mMOR-1O 
A comparison of the [35S]GTPγS binding curves were generated for 2 mu 
agonists, A. and B. Methadone, C. and D. Fentanyl, E. and F. 
Buprenorphine. The data was analyzed on GraphPad Prism using non-linear 
regression analysis. Results are the mean ± S.E. of at least three independent 
experiments.  
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Table 5 Effects of opioids on [35S]GTPγS binding in MOR-1 splice variants. [35S]GTPγS binding was performed with 
membranes (200µg) from stable cell lines containing the indicated cDNAs. 6 different C-terminal variants were 
characterized, mMOR-1, mMOR-1A, mMOR-1B1, mMOR-1C, mMOR-1E and mMOR-1O along with the control 
receptor MOR-TR-PK which is truncated after exon 3. Ki and EC50 values were calculated on GraphPad Prism using 
non-linear regression analysis. Analysis of variance followed by Bonferroni’s post-hoc test was performed to 
determine whether there were any significant differences between the receptors for the indicated drug. Results are 
the mean ± SEM of at least three independent experiments. For each variant, the data was normalized using 
stimulation of 10µM DAMGO. The data is reported as % Emax DAMGO to normalize for difference in receptor 
expression level across variants as well as the variability in basal stimulation from assay to assay. 
 
MOR-TR MOR-1 
Ligands 
G protein activation 
Ligands 
G protein activation 
Emax (% of 
DAMGO) EC50 (nM) 
Emax (% of 
DAMGO) EC50 (nM) 
DAMGO 100 49 ± 5 DAMGO 100 14 ± 2 
Morphine 72 ± 9 42 ± 8 Morphine 112 ± 10 30 ± 4 
b- Endorphin 137 ± 14 2830 ± 781 b- Endorphin 108 ± 9 91 ± 40 
Endomorphin1 110 ± 15 124 ± 56 Endomorphin1 99 ± 9 44 ± 8 
Endomorphin2 93 ± 3 52 ± 2 Endomorphin2 99 ± 8 95 ± 14 
Met-Enk-Arg-Phe 120 ± 6 80 ± 5 Met-Enk-Arg-Phe 98 ± 2 14 ± 5 
Methadone 120 ± 6 244 ± 7 Methadone 125 ± 12 25 ± 11 
Fentanyl 86 ± 12 180 ± 87 Fentanyl 95 ± 12 21 ± 1 
Buprenorphine 50 ±  12 7 ± 4 Buprenorphine 71 ±  13 7 ± 4 
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Table 5 continued. Effects of opioids on [35S]GTPγS binding in MOR-1 splice variants. [35S]GTPγS binding was 
performed with membranes (200µg) from stable cell lines containing the indicated cDNAs. 6 different C-terminal 
variants were characterized, mMOR-1, mMOR-1A, mMOR-1B1, mMOR-1C, mMOR-1E and mMOR-1O along with the 
control receptor MOR-TR-PK which is truncated after exon 3. Ki and EC50 values were calculated on GraphPad 
Prism using non-linear regression analysis. Analysis of variance followed by Bonferroni’s post-hoc test was performed 
to determine whether there were any significant differences between the receptors for the indicated drug. Results are 
the mean ± SEM of at least three independent experiments. For each variant, the data was normalized using 
stimulation of 10µM DAMGO. The data is reported as % Emax DAMGO to normalize for difference in receptor 
expression level across variants as well as the variability in basal stimulation from assay to assay. 
 
MOR-1A MOR-1B-1 
Ligands 
G protein activation 
Ligands 
G protein activation 
Emax (% of 
DAMGO) EC50 (nM) 
Emax (% of 
DAMGO) EC50 (nM) 
DAMGO 100 39 ± 15 DAMGO 100 115 ± 30 
Morphine 90 ± 9 26 ± 0.3 Morphine 96 ± 15 70 ± 17 
b- Endorphin 90 ± 5 95 ± 27 b- Endorphin 85 ± 3 152 ± 25 
Endomorphin1 104 ± 4 88 ± 24 Endomorphin1 102 ± 3 123 ± 34 
Endomorphin2 124 ± 4 138 ± 20 Endomorphin2 100 ± 13 356 ± 95 
Met-Enk-Arg-Phe 94 ± 3 13 ± 2 Met-Enk-Arg-Phe 92 ± 4 33 ± 16 
Methadone 118 ± 7 27 ± 11 Methadone 108 ± 13 207 ± 71 
Fentanyl 123 ± 14 23 ± 3 Fentanyl 91 ± 3 143 ± 52 
Buprenorphine 70 ±  3 16 ± 5 Buprenorphine 29 ±  6 52 ± 9 
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Table 5 continued. Effects of opioids on [35S]GTPγS binding in MOR-1 splice variants. [35S]GTPγS binding was 
performed with membranes (200µg) from stable cell lines containing the indicated cDNAs. 6 different C-terminal 
variants were characterized, mMOR-1, mMOR-1A, mMOR-1B1, mMOR-1C, mMOR-1E and mMOR-1O along with the 
control receptor MOR-TR-PK which is truncated after exon 3. Ki and EC50 values were calculated on GraphPad 
Prism using non-linear regression analysis. Analysis of variance followed by Bonferroni’s post-hoc test was performed 
to determine whether there were any significant differences between the receptors for the indicated drug. Results are 
the mean ± SEM of at least three independent experiments. For each variant, the data was normalized using 
stimulation of 10µM DAMGO. The data is reported as % Emax DAMGO to normalize for difference in receptor 
expression level across variants as well as the variability in basal stimulation from assay to assay. 
 
MOR-1C MOR-1E 
Ligands 
G protein activation 
Ligands 
G protein activation 
Emax (% of 
DAMGO) EC50 (nM) 
Emax (% of 
DAMGO) EC50 (nM) 
DAMGO 100 217 ± 82 DAMGO 100 25 ± 4 
Morphine 97 ± 4 56 ± 22 Morphine 102 ± 3 20 ± 2 
b- Endorphin 81 ± 4 111 ± 8 b- Endorphin 89 ± 5 22 ± 5 
Endomorphin1 94 ± 3 123 ± 34 Endomorphin1 109 ± 8 44 ± 16 
Endomorphin2 92 ± 6 111 ± 22 Endomorphin2 112 ± 5 105 ± 20 
Met-Enk-Arg-Phe 106 ± 6 71 ± 5 Met-Enk-Arg-Phe 97 ± 4 7 ± 0.5 
Methadone 188 ± 26 700 ± 71 Methadone 120 ± 14 13 ± 5 
Fentanyl 90 ± 6 60 ± 11 Fentanyl 104 ± 2 23 ± 7 
Buprenorphine 21 ± 5 0.08 ± 0.01 Buprenorphine 36 ±  10 2 ± 0.2 
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Table 5 continued. Effects of opioids on [35S]GTPγS binding in MOR-1 splice variants. [35S]GTPγS binding was 
performed with membranes (200µg) from stable cell lines containing the indicated cDNAs. 6 different C-terminal 
variants were characterized, mMOR-1, mMOR-1A, mMOR-1B1, mMOR-1C, mMOR-1E and mMOR-1O along with the 
control receptor MOR-TR-PK which is truncated after exon 3. Ki and EC50 values were calculated on GraphPad 
Prism using non-linear regression analysis. Analysis of variance followed by Bonferroni’s post-hoc test was performed 
to determine whether there were any significant differences between the receptors for the indicated drug. Results are 
the mean ± SEM of at least three independent experiments. For each variant, the data was normalized using 
stimulation of 10µM DAMGO. The data is reported as % Emax DAMGO to normalize for difference in receptor 
expression level across variants as well as the variability in basal stimulation from assay to assay. 
 
MOR-1O 
   Ligands G protein activation 
   
  Emax (% of DAMGO) EC50 (nM) 
   DAMGO 100 166 ± 9 
   Morphine 66 ± 3 133 ± 46 
   b- Endorphin 85 ± 2 210 ± 30 
   Endomorphin1 88 ± 5 342 ± 110 
   Endomorphin2 61 ± 5 360 ± 83 
   Met-Enk-Arg-Phe 91 ± 7 84 ± 16 
   Methadone 101 ± 4 107 ± 36 
   Fentanyl 112 ± 5 166 ± 24 
   Buprenorphine 33 ± 2 4 ± 3    
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Table 6 Significance values for EC50 values of drugs in Table 5. Analysis of variance followed by Bonferroni’s post-
hoc test was performed to determine whether there were any significant differences between the receptors for the 
indicated drug.  
 
EC50	
	       		 MOR-TR	 MOR-1	 MOR-1A	 MOR-1B	 MOR-1C	 MOR-1E	 MOR-1O	
DAMGO	 		 		 		 		 		 		 		
MOR-TR	 -	 NS	 NS	 NS	 NS	 NS	 NS	
MOR-1	 		 -	 NS	 NS	 P	≤	0.05	 NS	 NS	
MOR-1A	 		 		 -	 NS	 P	≤	0.05	 NS	 NS	
MOR-1B	 		 		 		 -	 NS	 P	≤	0.05	 NS	
MOR-1C	 		 		 		 		 -	 NS	 NS	
MOR-1E	 		 		 		 		 		 -	 NS	
MOR-1O	 		 		 		 		 		 		 -	
EC50	
	       		 MOR-TR	 MOR-1	 MOR-1A	 MOR-1B	 MOR-1C	 MOR-1E	 MOR-1O	
Morphine	 		 		 		 		 		 		 		
MOR-TR	 -	 NS	 NS	 NS	 NS	 NS	 P	≤	0.05	
MOR-1	 		 -	 NS	 NS	 NS	 NS	 P	≤	0.01	
MOR-1A	 		 		 -	 NS	 NS	 NS	 P	≤	0.01	
MOR-1B	 		 		 		 -	 NS	 NS	 NS	
MOR-1C	 		 		 		 		 -	 NS	 NS	
MOR-1E	 		 		 		 		 		 -	 P	≤	0.01	
MOR-1O	 		 		 		 		 		 		 -	
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Table 6 continued. Significance values for EC50 values of drugs in Table 5. Analysis of variance followed by 
Bonferroni’s post-hoc test was performed to determine whether there were any significant differences between the 
receptors for the indicated drug.  
EC50	
	       		 MOR-TR	 MOR-1	 MOR-1A	 MOR-1B	 MOR-1C	 MOR-1E	 MOR-1O	
b-Endorphin	 		 		 		 		 		 		 		
MOR-TR	 -	 P	≤	0.001	 P	≤	0.001	 P	≤	0.001	 P	≤	0.001	 P	≤	0.001	 P	≤	0.001	
MOR-1	 		 -	 NS	 NS	 NS	 NS	 NS	
MOR-1A	 		 		 -	 NS	 NS	 NS	 NS	
MOR-1B	 		 		 		 -	 NS	 NS	 NS	
MOR-1C	 		 		 		 		 -	 NS	 NS	
MOR-1E	 		 		 		 		 		 -	 NS	
MOR-1O	 		 		 		 		 		 		 -	
EC50	
	       		 MOR-TR	 MOR-1	 MOR-1A	 MOR-1B	 MOR-1C	 MOR-1E	 MOR-1O	
Endomorphin	
1	 		 		 		 		 		 		 		
MOR-TR	 -	 NS	 NS	 NS	 NS	 NS	 NS	
MOR-1	 		 -	 NS	 NS	 NS	 NS	 P	≤	0.05	
MOR-1A	 		 		 -	 NS	 NS	 NS	 NS	
MOR-1B	 		 		 		 -	 NS	 NS	 NS	
MOR-1C	 		 		 		 		 -	 NS	 NS	
MOR-1E	 		 		 		 		 		 -	 P	≤	0.05	
MOR-1O	 		 		 		 		 		 		 -	
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Table 6 continued Significance values for EC50 values of drugs in Table 5. Analysis of variance followed by 
Bonferroni’s post-hoc test was performed to determine whether there were any significant differences between the 
receptors for the indicated drug.  
 
EC50	
	       		 MOR-TR	 MOR-1	 MOR-1A	 MOR-1B	 MOR-1C	 MOR-1E	 MOR-1O	
Endomorphin	
2	 		 		 		 		 		 		 		
MOR-TR	 -	 NS	 NS	 P	≤	0.05	 NS	 NS	 P	≤	0.05	
MOR-1	 		 -	 NS	 P	≤	0.05	 NS	 NS	 P	≤	0.05	
MOR-1A	 		 		 -	 		 NS	 NS	 NS	
MOR-1B	 		 		 		 -	 NS	 NS	 NS	
MOR-1C	 		 		 		 		 -	 NS	 NS	
MOR-1E	 		 		 		 		 		 -	 NS	
MOR-1O	 		 		 		 		 		 		 -	
EC50	
	       		 MOR-TR	 MOR-1	 MOR-1A	 MOR-1B	 MOR-1C	 MOR-1E	 MOR-1O	
Met-Enk-Arg-
Phe	 		 		 		 		 		 		 		
MOR-TR	 -	 P	≤	0.01	 P	≤	0.01	 NS	 NS	 P	≤	0.01	 NS	
MOR-1	 		 -	 NS	 NS	 P	≤	0.05	 NS	 P	≤	0.01	
MOR-1A	 		 		 -	 NS	 P	≤	0.01	 NS	 P	≤	0.01	
MOR-1B	 		 		 		 -	 NS	 NS	 P	≤	0.05	
MOR-1C	 		 		
	
		 -	 P	≤	0.01	 NS	
MOR-1E	 		 		 		 		 		 -	 P	≤	0.001	
MOR-1O	 		 		 		 		 		 		 -	
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Table 6 continued. Significance values for EC50 values of drugs in Table 5. Analysis of variance followed by 
Bonferroni’s post-hoc test was performed to determine whether there were any significant differences between the 
receptors for the indicated drug.  
 
 
EC50	
	       		 MOR-TR	 MOR-1	 MOR-1A	 MOR-1B	 MOR-1C	 MOR-1E	 MOR-1O	
Methadone	 		 		 		 		 		 		 		
MOR-TR	 -	 NS	 NS	 NS	 P	≤	0.001	 NS	 NS	
MOR-1	 		 -	 NS	 NS	 P	≤	0.0001	 NS	 NS	
MOR-1A	 		 		 -	 NS	 P	≤	0.0001	 NS	 NS	
MOR-1B	 		 		 		 -	 P	≤	0.0001	 NS	 NS	
MOR-1C	 		 		 		 		 -	 P	≤	0.0001	 P	≤	0.0001	
MOR-1E	 		 		 		 		 		 -	 NS	
MOR-1O	 		 		 		 		 		 		 -	
EC50	
	       		 MOR-TR	 MOR-1	 MOR-1A	 MOR-1B	 MOR-1C	 MOR-1E	 MOR-1O	
Fentanyl	 		 		 		 		 		 		 		
MOR-TR	 -	 NS	 NS	 NS	 NS	 NS	 NS	
MOR-1	 		 -	 NS	 NS	 NS	 NS	 NS	
MOR-1A	 		 		 -	 NS	 NS	 NS	 NS	
MOR-1B	 		 		 		 -	 NS	 NS	 NS	
MOR-1C	 		 		
	
		 -	 NS	 NS	
MOR-1E	 		 		 		 		 		 -	 NS	
MOR-1O	 		 		 		 		 		 		 -	
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Table 6 continued. Significance values for EC50 values of drugs in Table 5. Analysis of variance followed by 
Bonferroni’s post-hoc test was performed to determine whether there were any significant differences between the 
receptors for the indicated drug.  
 
 
EC50	
	       		 MOR-TR	 MOR-1	 MOR-1A	 MOR-1B	 MOR-1C	 MOR-1E	 MOR-1O	
Buprenorphine	 		 		 		 		 		 		 		
MOR-TR	 -	 NS	 NS	 NS	 NS	 NS	 NS	
MOR-1	 		 -	 NS	 NS	 NS	 NS	 NS	
MOR-1A	 		 		 -	 NS	 NS	 NS	 NS	
MOR-1B	 		 		 		 -	 NS	 NS	 NS	
MOR-1C	 		 		
	
		 -	 NS	 NS	
MOR-1E	 		 		 		 		 		 -	 NS	
MOR-1O	 		 		 		 		 		 		 -	
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Table 7 Significance values for Emax values of drugs in Table 5. Analysis of variance followed by Bonferroni’s post-
hoc test was performed to determine whether there were any significant differences between the receptors for the 
indicated drug. 
Emax	
	       		 MOR-TR	 MOR-1	 MOR-1A	 MOR-1B	 MOR-1C	 MOR-1E	 MOR-1O	
DAMGO	 		 		 		 		 		 		 		
MOR-TR	 -	 NS	 NS	 NS	 NS	 NS	 NS	
MOR-1	 		 -	 NS	 NS	 NS	 NS	 NS	
MOR-1A	 		 		 -	 NS	 NS	 NS	 NS	
MOR-1B	 		 		 		 -	 NS	 NS	 NS	
MOR-1C	 		 		 		 		 -	 NS	 NS	
MOR-1E	 		 		 		 		 		 -	 NS	
MOR-1O	 		 		 		 		 		 		 -	
Emax	
	       		 MOR-TR	 MOR-1	 MOR-1A	 MOR-1B	 MOR-1C	 MOR-1E	 MOR-1O	
Morphine	 		 		 		 		 		 		 		
MOR-TR	 -	 NS	 NS	 NS	 NS	 NS	 NS	
MOR-1	 		 -	 NS	 NS	 NS	 NS	 P	≤	0.05	
MOR-1A	 		 		 -	 NS	 NS	 NS	 NS	
MOR-1B	 		 		 		 -	 NS	 NS	 NS	
MOR-1C	 		 		 		 		 -	 NS	 NS	
MOR-1E	 		 		 		 		 		 -	 NS	
MOR-1O	 		 		 		 		 		 		 -	
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Table 7 continued. Significance values for Emax values of drugs in Table 5. Analysis of variance followed by 
Bonferroni’s post-hoc test was performed to determine whether there were any significant differences between the 
receptors for the indicated drug. 
Emax	
	       		 MOR-TR	 MOR-1	 MOR-1A	 MOR-1B	 MOR-1C	 MOR-1E	 MOR-1O	
b-Endorphin	 		 		 		 		 		 		 		
MOR-TR	 -	 NS	 P	≤	0.01	 P	≤	0.01	 P	≤	0.01	 P	≤	0.01	 P	≤	0.01	
MOR-1	 		 -	 NS	 NS	 NS	 NS	 NS	
MOR-1A	 		 		 -	 NS	 NS	 NS	 NS	
MOR-1B	 		 		 		 -	 NS	 NS	 NS	
MOR-1C	 		 		 		 		 -	 NS	 NS	
MOR-1E	 		 		 		 		 		 -	 NS	
MOR-1O	 		 		 		 		 		 		 -	
Emax	
	       		 MOR-TR	 MOR-1	 MOR-1A	 MOR-1B	 MOR-1C	 MOR-1E	 MOR-1O	
Endomorphin	
1	 		 		 		 		 		 		 		
MOR-TR	 -	 NS	 NS	 NS	 NS	 NS	 NS	
MOR-1	 		 -	 NS	 NS	 NS	 NS	 NS	
MOR-1A	 		 		 -	 NS	 NS	 NS	 NS	
MOR-1B	 		 		 		 -	 NS	 NS	 NS	
MOR-1C	 		 		 		 		 -	 NS	 NS	
MOR-1E	 		 		 		 		 		 -	 NS	
MOR-1O	 		 		 		 		 		 		 -	
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Table 7 continued. Significance values for Emax values of drugs in Table 5. Analysis of variance followed by 
Bonferroni’s post-hoc test was performed to determine whether there were any significant differences between the 
receptors for the indicated drug. 
 
Emax	
	       		 MOR-TR	 MOR-1	 MOR-1A	 MOR-1B	 MOR-1C	 MOR-1E	 MOR-1O	
Endomorphin	
2	 		 		 		 		 		 		 		
MOR-TR	 -	 NS	 NS	 NS	 NS	 NS	 NS	
MOR-1	 		 -	 NS	 NS	 NS	 NS	 P	≤	0.05	
MOR-1A	 		 		 -	 		 NS	 NS	 P	≤	0.001	
MOR-1B	 		 		 		 -	 NS	 NS	 P	≤	0.05	
MOR-1C	 		 		 		 		 -	 NS	 NS	
MOR-1E	 		 		 		 		 		 -	 P	≤	0.01	
MOR-1O	 		 		 		 		 		 		 -	
Emax	
	       		 MOR-TR	 MOR-1	 MOR-1A	 MOR-1B	 MOR-1C	 MOR-1E	 MOR-1O	
Met-Enk-Arg-
Phe	 		 		 		 		 		 		 		
MOR-TR	 -	 NS	 P	≤	0.05	 P	≤	0.05	 NS	 NS	 P	≤	0.05	
MOR-1	 		 -	 NS	 NS	 NS	 NS	 NS	
MOR-1A	 		 		 -	 NS	 NS	 NS	 NS	
MOR-1B	 		 		 		 -	 NS	 NS	 NS	
MOR-1C	 		 		
	
		 -	 NS	 NS	
MOR-1E	 		 		 		 		 		 -	 NS	
MOR-1O	 		 		 		 		 		 		 -	
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Table 7 continued. Significance values for Emax values of drugs in Table 5. Analysis of variance followed by 
Bonferroni’s post-hoc test was performed to determine whether there were any significant differences between the 
receptors for the indicated drug.	
	
Emax	
	       		 MOR-TR	 MOR-1	 MOR-1A	 MOR-1B	 MOR-1C	 MOR-1E	 MOR-1O	
Methadone	 		 		 		 		 		 		 		
MOR-TR	 -	 NS	 NS	 NS	 NS	 NS	 NS	
MOR-1	 		 -	 NS	 NS	 NS	 NS	 NS	
MOR-1A	 		 		 -	 NS	 NS	 NS	 NS	
MOR-1B	 		 		 		 -	 P	≤	0.05	 NS	 NS	
MOR-1C	 		 		 		 		 -	 NS	 P	≤	0.01	
MOR-1E	 		 		 		 		 		 -	 NS	
MOR-1O	 		 		 		 		 		 		 -	
Emax	
	       		 MOR-TR	 MOR-1	 MOR-1A	 MOR-1B	 MOR-1C	 MOR-1E	 MOR-1O	
Fentanyl	 		 		 		 		 		 		 		
MOR-TR	 -	 NS	 NS	 NS	 NS	 NS	 NS	
MOR-1	 		 -	 NS	 NS	 NS	 NS	 NS	
MOR-1A	 		 		 -	 NS	 NS	 NS	 NS	
MOR-1B	 		 		 		 -	 NS	 NS	 NS	
MOR-1C	 		 		
	
		 -	 NS	 NS	
MOR-1E	 		 		 		 		 		 -	 NS	
MOR-1O	 		 		 		 		 		 		 -	
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Table 7 continued. Significance values for Emax values of drugs in Table 5. Analysis of variance followed by 
Bonferroni’s post-hoc test was performed to determine whether there were any significant differences between the 
receptors for the indicated drug.	
	
	
Emax	
	       		 MOR-TR	 MOR-1	 MOR-1A	 MOR-1B	 MOR-1C	 MOR-1E	 MOR-1O	
Buprenorphine	 		 		 		 		 		 		 		
MOR-TR	 -	 NS	 NS	 NS	 NS	 NS	 NS	
MOR-1	 		 -	 NS	 NS	 P	≤	0.05	 NS	 NS	
MOR-1A	 		 		 -	 NS	 P	≤	0.05	 NS	 NS	
MOR-1B	 		 		 		 -	 NS	 NS	 NS	
MOR-1C	 		 		
	
		 -	 NS	 NS	
MOR-1E	 		 		 		 		 		 -	 NS	
MOR-1O	 		 		 		 		 		 		 -	
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Part II - C-terminal splice variants differentially regulate β – 
arrestin-2 signaling pathways 
 
The recent focus in the opioid field has been on biased agonism to 
develop opioid drugs that can preferentially activate certain signaling 
pathways (Bohn et al., 2000; Raehal et al., 2005). As described in Part 
I, the main purpose of this study is to explore if the differences at the 
C-terminus of the receptor ultimately lead to differences in signal 
transduction and its ability to recruit proteins to the receptor complex. 
We are specifically interested in 2 crucial GPCR signaling pathways – 
the G protein pathway and the β-arrestin pathway. The opioid 
response is mediated in conjunction by G protein and β-arrestin 
signaling pathways and distinct biological functions are often linked to 
these different pathways. GPCRs adopt multiple conformations and 
the binding of different ligands to the same receptor can stabilize 
distinct conformations leading to diverse signaling profiles. For 
example, an agonist capable of fully stimulating G protein coupling 
may show very little efficacy in activating the β-arrestin pathway and 
vice versa. The concept of biased agonism describes this difference in 
ligand-directed GPCR signaling. Ligands that have the capability of 
differentially stimulating the canonical and non-canonical 
transduction pathways are considered biased agonists.  
 
Much of the recent effort in the field has focused on developing biased 
agonists that activate only the subset of signaling pathways important 
for the therapeutic effect while limiting the unwanted side effects 
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(Raehal et al., 2011). However, since receptor internalization by β-
arrestins can lead to both desensitization and resensitization 
pathways, there seems to be a divide in the literature on the precise 
role of β-arrestins in opioid action. This leads to an evident discord in 
which signaling bias is therapeutically beneficial. Recently developed G 
protein biased agonists like, Herkinorin and TRV130, have shown to 
display enhanced analgesia with reduced side effects like 
gastrointestinal dysfunction and respiratory depression (DeWire et al., 
2013; Groer et al., 2007). However, drugs based on the structure of 
endomorphins, which are arrestin biased, also appear to have 
favorable analgesic profile with fewer adverse effects (Varamini et al., 
2012; Wilson et al., 2000). Some of these inconsistencies may arise 
because most of the studies that look at bias among ligands only focus 
on one receptor variant of Oprm – the MOR-1 receptor. However, more 
than one receptor subtype exists endogenously. Clinical observations 
as well as opioid literature support the existence of multiple mu opioid 
receptors. 
 
In Part I, we established that the different C-terminal splice variants 
exhibit differences in signaling pattern through the G protein signaling 
pathway. Here, we wanted to extend this understanding to the β-
arrestin-2 signaling pathway. The C-terminal splice variants show a 
great deal of heterogeneity in their in-vivo expression pattern as well 
as in-vitro pharmacology. Their expression is known to differ in a 
regional as well as cell-type specific manner (Abbadie et al., 2000; 
Abbadie et al., 2004). Studying the biases in the β-arrestin-2 signaling 
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pathway would further our understanding of how an in-vitro drug 
profile could translate into endogenous functional effects.  This focus 
on splice variants is complementary to research on ligand bias and 
hetero-oligomerization as we anticipate that different splice variants 
are likely to interact with different complement of proteins to mediate 
their effects. 
 
The µ-OR variants contain serine and threonine residues in their 
cytoplasmic tails that represent phosphoacceptor sites for GPCR 
kinases. Earlier studies have demonstrated that the C-terminal 
receptor variants differ in their agonist selective phosphorylation, 
internalization and down-regulation. Whole cell phosphorylation 
studies show that DAMGO induces an increased phosphorylation in 
the mMOR-1 and mMOR-1D variants in comparison to mMOR-1C and 
mMOR-1E variants (Koch et al., 2001). Koch et al. also showed that 
levels of phosphorylation observed in these variants is both agonist 
dependent as well as variant dependent. In contrast to the pattern 
observed with DAMGO induced phosphorylation, morphine induced 
similar levels of phosphorylation in the mMOR-1D and mMOR-1E 
receptors but markedly low levels of phosphorylation in the mMOR-1 
and mMOR-1C receptor. Changing the Thr-394 residue in the exon 4 
portion of MOR-1 into alanine results in a reduction of DAMGO-
induced phosphorylation and a slower DAMGO-mediated 
desensitization of the T394A receptor mutant (Wolf et al., 1999; Pak et 
al., 1997). In addition, the lack of Thr-394 leads to facilitated receptor 
internalization, enhanced resensitization, and recycling of the T394A 
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receptor mutant (Koch et al., 1998). This indicates that Thr394 is a 
potential β–arrestin recruiting site in the exon 4 region of the C-tail. 
Other studies have shown Ser375 to be another β–arrestin recruiting 
site present in the exon 3 region of the mu receptor (Lau et al., 2011, 
Moulédous et al., 2015). 
 
Since phosphorylation of the C-tail is a pre-requisite for β-arrestin 
recruitment, these studies suggest that there might also be differences 
in levels of β-arrestin recruitment across these variants. These 
differences may be due to availability of phosphorylation sites or 
protein kinases. In addition, different agonists might phosphorylate 
different Ser/Thr residues through different mechanisms. For 
example, DAMGO is known to cause receptor phosphorylation through 
GRKs whereas Morphine is known to recruit PKA.  
 
We used the DiscoverX PathHunter assay with the clonal cell lines 
described in Part I to study splice variant specific patterns in drug 
induced β–arrestin-2 recruitment. We studied 6 different splice 
variants, mMOR-1-PK, mMOR-1A-PK, mMOR-1B1-PK, mMOR-1C-PK, 
mMOR-1E-PK and mMOR-1O-PK as well as a control receptor mMOR-
TR-PK which is truncated after exon 3. We thought it was important to 
have the control receptor because the conserved part of the C-tail as 
encoded by exon 3 contains a β–arrestin-2 recruiting phosphorylation 
site at Ser375 (Lau et al., 2011, Moulédous et al., 2015). Therefore, the 
C-terminal splice variants with splicing downstream of exon 3, not 
only contain the Ser375 phosphorylation site but might also contain  
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Figure 16 DiscoverX PathHunter assay to measure agonist induced β-arrestin-
2 recruitment across the various C-terminal splice variants 
Left panel: variants mMOR-TR, mMOR-1, mMOR-1A and mMOR-1B 
Right panel: variants mMOR-TR, mMOR-1C, mMOR-1E, mMOR-1O 
A comparison of the β-arrestin-2 recruitment curves were generated for 3 mu 
agonists, A. and B. DAMGO, C. and D. Morphine, E. and F. b-Endorphin. The 
data was analyzed on GraphPad Prism using non-linear regression analysis. 
Results are the mean ± S.E. of at least three independent experiments. 
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Figure 17 DiscoverX PathHunter assay to measure agonist induced β-
arrestin-2 recruitment across the various C-terminal splice variants 
Left panel: variants mMOR-TR, mMOR-1, mMOR-1A and mMOR-1B 
Right panel: variants mMOR-TR, mMOR-1C, mMOR-1E, mMOR-1O 
A comparison of the β-arrestin-2 recruitment curves were generated for 3 mu 
agonists, A. and B. Endomorphin1, C. and D. Endomorphin2, E. and F. 
Fentanyl. The data was analyzed on GraphPad Prism using non-linear 
regression analysis. Results are the mean ± S.E. of at least three independent 
experiments. 
  
 97 
  
Ba
sa
l -10 -9 -8 -7 -6 -5
0
100
200
300
[Methadone, log M]
%
 D
A
M
G
O
 E
m
ax
MOR-TR
MOR-1
MOR-1A
MOR-1B
Ba
sa
l -10 -9 -8 -7 -6 -5
0
100
200
300
[Methadone, log M]
%
 D
A
M
G
O
 E
m
ax
MOR-TR
MOR-1C
MOR-1E
MOR-1O
Ba
sa
l -10 -9 -8 -7 -6 -5
0
100
200
[Met-Enk-Arg-Phe, log M]
%
 D
A
M
G
O
 E
m
ax
MOR-TR
MOR-1C
MOR-1E
MOR-1O
Ba
sa
l -10 -9 -8 -7 -6 -5
0
50
100
150
200
[Met-Enk-Arg-Phe, log M]
%
 D
A
M
G
O
 E
m
ax
MOR-TR
MOR-1
MOR-1A
MOR-1B
A B 
C D 
Ba
sa
l -10 -9 -8 -7 -6 -5
0
50
100
[Buprenorphine, log M]
%
 D
A
M
G
O
 E
m
ax
MOR-TR
MOR-1
MOR-1A
MOR-1B
Ba
sa
l -10 -9 -8 -7 -6 -5
0
50
100
[Buprenorphine, log M]
%
 D
A
M
G
O
 E
m
ax
MOR-TR
MOR-1C
MOR-1E
MOR-1O
E F 
Figure 18 DiscoverX PathHunter assay to measure agonist induced β-
arrestin-2 recruitment across the various C-terminal splice variants 
Left panel: variants mMOR-TR, mMOR-1, mMOR-1A and mMOR-1B 
Right panel: variants mMOR-TR, mMOR-1C, mMOR-1E, mMOR-1O 
A comparison of the β-arrestin-2 recruitment curves were generated for 2 mu 
agonists, A. and B. Methadone, C. and D. Met-Enk-Arg-Phe, E. and F. 
Buprenorphine. The data was analyzed on GraphPad Prism using non-linear 
regression analysis. Results are the mean ± S.E. of at least three independent 
experiments. 
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additional phosphorylation sites downstream of exon 3. This study 
would help us determine if the ability of the conserved β–arrestin-2 
phosphorylation site may vary across the variants and if adding more 
amino acids at the C-tail might enhance or impede its ability to recruit 
arrestins. Figures 16, 17 and 18 depict the arrestin recruitment 
pattern as seen in these variants in response to a number of mu 
agonists. The results have been normalized to % DAMGO Emax for 
every variant in order to eliminate any inherent system bias as a result 
of difference in expression pattern or basal levels of β–arrestin-2 
recruitment. 
 
We screened a panel of peptides and non-peptide opioid agonists and 
observed differences in both Emax and EC50 values across the 
different variants tested. The control MOR-TR-PK receptor, which has 
a truncated C-tail, was significantly more effective at recruiting β–
arrestin-2 in comparison to any of the other splice variants. Emax and 
EC50 values are shown in Table 8. Methadone, a non-peptide agonist, 
showed a similar trend but a more significant difference between the 
control receptor and the other splice variants. Methadone stimulated a 
robust β–arrestin-2 response of Emax - 638% of DAMGO at the 
mMOR-TR-PK receptor. Adding just 4 amino acids to the control 
receptor in mMOR-1A-PK significantly impeded its ability to recruit 
arrestin (Emax – 65% of DAMGO).  
 
The increased efficiency of the mMOR-TR-PK receptor at recruiting β–
arrestin-2, however, was not conserved for all the drugs. 
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Endomorphin1 acted as a partial agonist in the β–arrestin-2 assay at 
the control receptor (Emax – 66% of DAMGO) but as a full agonist at 
the mMOR-1A receptor (Emax- 108% of DAMGO). Another peptide 
agonist, Met-Enk-Arg-Phe was twice as effective at recruiting β–
arrestin-2 at the mMOR-1C-PK receptor (Emax- 224% of DAMGO) in 
comparison to mMOR-TR-PK (Emax - 104% of DAMGO). 
 
mMOR-1C and mMOR-1O variants have exon 7 at the C-tail and 
overlap in 30 amino acids downstream of exon 3. In addition to exon 7, 
mMOR-1C also contains exons 8, 9 and an extra 22 amino acids in the 
C-tail. In spite of the similarity in between these 2 variants, they show 
significant variations in their agonist induced arrestin recruitment 
pattern. For example, the two receptors are equally effective in the β – 
endorphin induced arrestin response, but the mMOR-1O receptor is 8 
times more potent in comparison to mMOR-1C. This trend is reversed 
for Endomorphin 2 and Methadone induced response, where the 
mMOR-1C receptor is significantly more potent in comparison to the 
mMOR-1O receptor. One possible reason is that in spite of the 
sequence similarity, the alternatively spliced sequences contain 
differential phosphorylation sites that influence their function. mMOR-
1C has the longest C-terminal tail across all C-terminal splice variants 
with 52 amino acids. The long C-terminal tail may modify the 
structure of the receptor and impact its ability to interact with other 
protein complexes. 
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The pattern of β–arrestin-2 recruitment varies across drugs as well as 
across variants. It is also interesting that in spite of the presence of 
conserved potential phosphorylation sites in exon 3 part of the C-tail, 
most of the C-terminal splice variants are less effective at recruiting β-
arrestin-2 in comparison to the control mMOR-TR receptor. The 
response seems to follow a bell curve when correlating the length of 
the C-tail to arrestin recruitment efficiency, where the mMOR-1C and 
mMOR-1O receptors with the longer C-tails are much more like the 
truncated receptor in their ability to recruit arrestin. These assays, 
however, do not provide sufficient evidence regarding the relevance of 
these findings in-vivo since β–arrestins can affect a number of 
downstream pathways. Arrestins have been shown to act as scaffolds 
for both internalization and ubiquitination machinery.  
 
Alternatively, ERK1/2 activation has also been linked to receptor 
desensitization through arrestin-dependent and arrestin-independent 
mechanisms. We measured ERK1/2 activation in two C-terminal 
variants mMOR-1 and mMOR-1O expressed in HEK cells (Figure 19). 
Using the drugs that showed us the most differences across variants, 
we measured ERK1/2 activation as a way to validate our earlier 
findings. We chose to use western blot analysis as it is a whole cell 
assay instead of an in vitro assay like the [35S]GTPγS. Additionally, we 
did this assay in another cell line, HEK cells, to test the applicability of 
our earlier results. We chose 2 of the C-terminal variants, mMOR-1 
and mMOR-1O, that had the most differences from our earlier 
findings. We compared levels of ERK activation in these variants after  
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Figure 19 Agonist induced ERK activation in HEK cells expressing MOR-1 
and MOR-1O receptor. A. Western blot showing total ERK levels in HEK 
cells expressing the receptor variant after saline, DAMGO, Buprenorphine 
or Fentanyl treatment. B. Western blot showing p-ERK levels in HEK cells 
expressing the receptor variant after saline, DAMGO, Buprenorphine or 
Fentanyl treatment. C. Fold change in ERK1/2 activation after agonist 
treatment at MOR-1. The results are from three independent experiments. 
The p-ERK levels were normalized to total ERK. D. Fold change in ERK1/2 
activation after agonist treatment at MOR-1O. The results are from three 
independent experiments. The p-ERK levels were normalized to total ERK. 
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treatment with 3 different agonists- DAMGO, Buprenorphine and 
Fentanyl at their equi-active [35S]GTPγS dose. The HEK cell lines 
expressing the receptor variants showed no significant differences in 
pERK activation after agonist treatment. ERK results can sometimes 
be inconclusive because the ERK pathway can be activated through 
both G protein as well as arrestin dependent mechanism. However, we 
think that since we used equi-active [35S]GTPγS doses for these 
assays, the ERK results serve as a validation of our results in the 
[35S]GTPγS assay. In addition, it also suggests that the cytoplasmic 
pERK activation we are observing in the western blot assay is 
primarily through a G protein dependent mechanism. 
 
The differences in β-arrestin activity observed across the variants 
could be due to several reasons. Firstly, it is possible that the 
phosphorylation sites in the conserved portion of the exon 3 C-tail are 
not equally active across the different C-terminal variants. The 
differences in length and conformation of the C-tail can affect the 
accessibility of these sites to the GPCR kinases. Secondly, the 
differences could be due to the differences downstream of exon 3 at 
the tip of the C-terminus.  Some of these variants may potentially have 
additional phosphorylation and β-arrestin recruiting sites downstream 
of exon 3. There might also be differences in their ability to interact 
with other protein kinases. A follow up study should look at the 
relevance of the Ser375 β-arrestin recruiting site across the different 
variants and also explore the presence of additional active 
 103 
phosphorylation sites downstream of exon 3, specifically at variants 
like MOR-1O which are more effective in recruiting β-arrestin. 
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Table 8 Effect of mu agonist on β-arrestin-2 recruitment in CHO cells stably transfected with the C-terminal splice 
variant. A PathHunter β-arrestin-2 assay (DiscoverX) were performed as described in Methods. 6 different C-terminal 
variants were characterized, mMOR-1, mMOR-1A, mMOR-1B1, mMOR-1C, mMOR-1E and mMOR-1O along with the 
control receptor MOR-TR-PK which is truncated after exon 3. Ki and EC50 values were calculated on GraphPad 
Prism using non-linear regression analysis. Analysis of variance followed by Bonferroni’s post-hoc test was performed 
to determine whether there were any significant differences between the receptors for the indicated drug.  Results are 
the mean ± SEM of at least three independent experiments. For each variant, the data was normalized using 
stimulation of 10µM DAMGO. The data is reported as % Emax DAMGO to normalize for difference in receptor 
expression level across variants as well as the variability in basal stimulation from assay to assay. 
 
 
MOR-TR MOR-1 
Ligands 
Arrestin activation 
Ligands 
Arrestin activation 
Emax (% of 
DAMGO) EC50 (nM) 
Emax (% of 
DAMGO) EC50 (nM) 
DAMGO 100 146 ± 16 DAMGO 100 113 ± 20 
Morphine 40 ± 2 350 ± 89 Morphine 15 ± 1 147 ± 19 
b- Endorphin 68 ± 5 383 ± 38 b- Endorphin 55 ± 6 315 ± 66 
Endomorphin1 66 ± 8 92 ± 14 Endomorphin1 62 ± 6 118 ± 23 
Endomorphin2 74 ± 6 75 ± 15 Endomorphin2 52 ± 4 184 ± 37 
Met-Enk-Arg-Phe 104 ± 13 78 ± 34 Met-Enk-Arg-Phe 58 ± 5 308 ± 70 
Methadone 638 ± 58 97 ± 19 Methadone 59 ± 7 263 ± 59 
Fentanyl 69 ± 5 35 ± 4 Fentanyl 65 ± 16 39 ± 5 
Buprenorphine No Signal No Signal Buprenorphine No Signal No Signal 
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Table 8 continued. Effect of mu agonist on β-arrestin-2 recruitment in CHO cells stably transfected with the C-
terminal splice variant. A PathHunter β-arrestin-2 assay (DiscoverX) were performed as described in Methods. 6 
different C-terminal variants were characterized, mMOR-1, mMOR-1A, mMOR-1B1, mMOR-1C, mMOR-1E and 
mMOR-1O along with the control receptor MOR-TR-PK which is truncated after exon 3. Ki and EC50 values were 
calculated on GraphPad Prism using non-linear regression analysis. Analysis of variance followed by Bonferroni’s 
post-hoc test was performed to determine whether there were any significant differences between the receptors for 
the indicated drug.  Results are the mean ± SEM of at least three independent experiments. For each variant, the 
data was normalized using stimulation of 10µM DAMGO. The data is reported as % Emax DAMGO to normalize for 
difference in receptor expression level across variants as well as the variability in basal stimulation from assay to 
assay. 
 
MOR-1A MOR-1B-1 
Ligands 
Arrestin activation 
Ligands 
Arrestin activation 
Emax (% of 
DAMGO) EC50 (nM) 
Emax (% of 
DAMGO) EC50 (nM) 
DAMGO 100 167 ± 2 DAMGO 100 193 ± 40 
Morphine 15 ± 0.5 123 ± 4 Morphine 19 ± 2 332 ± 112 
b- Endorphin 45 ± 12 462 ± 116 b- Endorphin 62 ± 3 634 ± 47 
Endomorphin1 108 ± 7 668 ± 213 Endomorphin1 85 ± 5 115 ± 16 
Endomorphin2 92 ± 7 630 ± 183 Endomorphin2 72 ± 4 382 ± 88 
Met-Enk-Arg-Phe 125 ± 8 1014 ± 56 Met-Enk-Arg-Phe 83 ± 8 1085 ± 260 
Methadone 65 ± 2 200 ± 46 Methadone 98 ± 3 263 ± 43 
Fentanyl 62 ± 8 39 ± 7 Fentanyl 89 ± 7 42 ± 5 
Buprenorphine No Signal No Signal Buprenorphine No Signal No Signal 
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Table 8 continued. Effect of mu agonist on β-arrestin-2 recruitment in CHO cells stably transfected with the C-
terminal splice variant. A PathHunter β-arrestin-2 assay (DiscoverX) were performed as described in Methods. 6 
different C-terminal variants were characterized, mMOR-1, mMOR-1A, mMOR-1B1, mMOR-1C, mMOR-1E and 
mMOR-1O along with the control receptor MOR-TR-PK which is truncated after exon 3. Ki and EC50 values were 
calculated on GraphPad Prism using non-linear regression analysis. Analysis of variance followed by Bonferroni’s 
post-hoc test was performed to determine whether there were any significant differences between the receptors for 
the indicated drug.  Results are the mean ± SEM of at least three independent experiments. For each variant, the 
data was normalized using stimulation of 10µM DAMGO. The data is reported as % Emax DAMGO to normalize for 
difference in receptor expression level across variants as well as the variability in basal stimulation from assay to 
assay. 
 
MOR-1C MOR-1E 
Ligands 
Arrestin activation 
Ligands 
Arrestin activation 
Emax (% of 
DAMGO) EC50 (nM) 
Emax (% of 
DAMGO) EC50 (nM) 
DAMGO 100 355 ± 94 DAMGO 100 211 ± 64 
Morphine 18 ± 1 195 ± 16  Morphine 28 ± 3 48 ± 6 
b- Endorphin 37 ± 2 806 ± 180 b- Endorphin 51 ± 1 326 ± 22 
Endomorphin1 72 ± 2 225 ± 23 Endomorphin1 72 ± 3 360 ± 37 
Endomorphin2 46 ± 6 163 ± 28 Endomorphin2 61 ± 6 400 ± 217 
Met-Enk-Arg-Phe 224 ± 44 494 ± 178 Met-Enk-Arg-Phe 83 ± 4 1951 ± 906 
Methadone 67 ± 16 407 ± 182 Methadone 54 ± 2 352 ± 111 
Fentanyl 49 ± 2 48 ± 4 Fentanyl 53 ± 2 84 ± 17 
Buprenorphine No Signal No Signal Buprenorphine No Signal No Signal 
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Table 8 continued. Effect of mu agonist on β-arrestin-2 recruitment in CHO cells stably transfected with the C-
terminal splice variant. A PathHunter β-arrestin-2 assay (DiscoverX) were performed as described in Methods. 6 
different C-terminal variants were characterized, mMOR-1, mMOR-1A, mMOR-1B1, mMOR-1C, mMOR-1E and 
mMOR-1O along with the control receptor MOR-TR-PK which is truncated after exon 3. Ki and EC50 values were 
calculated on GraphPad Prism using non-linear regression analysis. Analysis of variance followed by Bonferroni’s 
post-hoc test was performed to determine whether there were any significant differences between the receptors for 
the indicated drug.  Results are the mean ± SEM of at least three independent experiments. For each variant, the 
data was normalized using stimulation of 10µM DAMGO. The data is reported as % Emax DAMGO to normalize for 
difference in receptor expression level across variants as well as the variability in basal stimulation from assay to 
assay. 
 
MOR-1O 
   
Ligands 
Arrestin activation 
   Emax (% of 
DAMGO) EC50 (nM) 
   DAMGO 100 94 ± 34 
   Morphine 25 ± 0.5 190 ± 19 
   b- Endorphin 37 ± 9 159 ± 36 
   Endomorphin1 78 ± 3 127 ± 4 
   Endomorphin2 94 ± 17 876 ± 541 
   Met-Enk-Arg-Phe 56 ± 9 463 ± 163 
   Methadone 80 ± 2 97 ± 19 
   Fentanyl 83 ± 1 31 ± 5 
   Buprenorphine No Signal No Signal    
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Table 9 Significance values for EC50 values of drugs in Table 8. Analysis of variance followed by Bonferroni’s post-
hoc test was performed to determine whether there were any significant differences between the receptors for the 
indicated drug. 
EC50	
	       		 MOR-TR	 MOR-1	 MOR-1A	 MOR-1B	 MOR-1C	 MOR-1E	 MOR-1O	
DAMGO	 		 		 		 		 		 		 		
MOR-TR	 -	 NS	 NS	 NS	 NS	 NS	 NS	
MOR-1	 		 -	 NS	 NS	 NS	 NS	 NS	
MOR-1A	 		 		 -	 NS	 NS	 NS	 NS	
MOR-1B	 		 		 		 -	 NS	 NS	 NS	
MOR-1C	 		 		 		 		 -	 NS	 P	≤	0.05	
MOR-1E	 		 		 		 		 		 -	 NS	
MOR-1O	 		 		 		 		 		 		 -	
	        EC50	
	       		 MOR-TR	 MOR-1	 MOR-1A	 MOR-1B	 MOR-1C	 MOR-1E	 MOR-1O	
Morphine	 		 		 		 		 		 		 		
MOR-TR	 -	 NS	 NS	 NS	 NS	 P	≤	0.05	 NS	
MOR-1	 		 -	 NS	 NS	 NS	 NS	 NS	
MOR-1A	 		 		 -	 NS	 NS	 NS	 NS	
MOR-1B	 		 		 		 -	 NS	 NS	 NS	
MOR-1C	 		 		 		 		 -	 NS	 NS	
MOR-1E	 		 		 		 		 		 -	 NS	
MOR-1O	 		 		 		 		 		 		 -	
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Table 9 continued. Significance values for EC50 values of drugs in Table 8. Analysis of variance followed by 
Bonferroni’s post-hoc test was performed to determine whether there were any significant differences between the 
receptors for the indicated drug. 
	
EC50	
	       		 MOR-TR	 MOR-1	 MOR-1A	 MOR-1B	 MOR-1C	 MOR-1E	 MOR-1O	
b-Endorphin	 		 		 		 		 		 		 		
MOR-TR	 -	 NS	 NS	 NS	 NS	 NS	 NS	
MOR-1	 		 -	 NS	 NS	 P	≤	0.05	 NS	 NS	
MOR-1A	 		 		 -	 NS	 NS	 NS	 NS	
MOR-1B	 		 		 		 -	 NS	 NS	 P	≤	0.05	
MOR-1C	 		 		 		 		 -	 P	≤	0.05	 P	≤	0.01	
MOR-1E	 		 		 		 		 		 -	 NS	
MOR-1O	 		 		 		 		 		 		 -	
	        EC50	
	       		 MOR-TR	 MOR-1	 MOR-1A	 MOR-1B	 MOR-1C	 MOR-1E	 MOR-1O	
Endomorphin	1	 		 		 		 		 		 		 		
MOR-TR	 -	 NS	 P	≤	0.01	 NS	 NS	 NS	 NS	
MOR-1	 		 -	 P	≤	0.01	 NS	 NS	 NS	 NS	
MOR-1A	 		 		 -	 P	≤	0.01	 P	≤	0.05	 NS	 P	≤	0.01	
MOR-1B	 		 		 		 -	 NS	 NS	 NS	
MOR-1C	 		 		 		 		 -	 NS	 NS	
MOR-1E	 		 		 		 		 		 -	 NS	
MOR-1O	 		 		 		 		 		 		 -	
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Table 9 continued. Significance values for EC50 values of drugs in Table 8. Analysis of variance followed by 
Bonferroni’s post-hoc test was performed to determine whether there were any significant differences between the 
receptors for the indicated drug. 
	
EC50	
	       		 MOR-TR	 MOR-1	 MOR-1A	 MOR-1B	 MOR-1C	 MOR-1E	 MOR-1O	
Endomorphin	2	 		 		 		 		 		 		 		
MOR-TR	 -	 NS	 NS	 NS	 NS	 NS	 NS	
MOR-1	 		 -	 NS	 NS	 NS	 NS	 NS	
MOR-1A	 		 		 -	 NS	 NS	 NS	 NS	
MOR-1B	 		 		 		 -	 NS	 NS	 NS	
MOR-1C	 		 		 		 		 -	 NS	 NS	
MOR-1E	 		 		 		 		 		 -	 NS	
MOR-1O	 		 		 		 		 		 		 -	
	        EC50	
	       		 MOR-TR	 MOR-1	 MOR-1A	 MOR-1B	 MOR-1C	 MOR-1E	 MOR-1O	
Met-Enk-Arg-Phe	 		 		 		 		 		 		 		
MOR-TR	 -	 NS	 NS	 NS	 NS	 NS	 NS	
MOR-1	 		 -	 NS	 NS	 NS	 NS	 NS	
MOR-1A	 		 		 -	 NS	 NS	 NS	 NS	
MOR-1B	 		 		 		 -	 NS	 NS	 NS	
MOR-1C	 		 		 		 		 -	 NS	 NS	
MOR-1E	 		 		 		 		 		 -	 NS	
MOR-1O	 		 		 		 		 		 		 -	
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Table 9 continued. Significance values for EC50 values of drugs in Table 8. Analysis of variance followed by 
Bonferroni’s post-hoc test was performed to determine whether there were any significant differences between the 
receptors for the indicated drug. 
	
EC50	
	       		 MOR-TR	 MOR-1	 MOR-1A	 MOR-1B	 MOR-1C	 MOR-1E	 MOR-1O	
Methadone	 		 		 		 		 		 		 		
MOR-TR	 -	 P	≤	0.0001	 P	≤	0.0001	 P	≤	0.0001	 P	≤	0.0001	 P	≤	0.0001	 P	≤	0.0001	
MOR-1	 		 -	 NS	 NS	 NS	 NS	 NS	
MOR-1A	 		 		 -	 NS	 NS	 NS	 NS	
MOR-1B	 		 		 		 -	 NS	 NS	 NS	
MOR-1C	 		 		 		 		 -	 NS	 NS	
MOR-1E	 		 		 		 		 		 -	 NS	
MOR-1O	 		 		 		 		 		 		 -	
	        EC50	
	       		 MOR-TR	 MOR-1	 MOR-1A	 MOR-1B	 MOR-1C	 MOR-1E	 MOR-1O	
Fentanyl	 		 		 		 		 		 		 		
MOR-TR	 -	 NS	 NS	 NS	 NS	 P	≤	0.05	 NS	
MOR-1	 		 -	 NS	 NS	 NS	 P	≤	0.05	 NS	
MOR-1A	 		 		 -	 NS	 NS	 P	≤	0.05	 NS	
MOR-1B	 		 		 		 -	 NS	 P	≤	0.05	 NS	
MOR-1C	 		 		 		 		 -	 NS	 P	≤	0.01	
MOR-1E	 		 		 		 		 		 -	 NS	
MOR-1O	 		 		 		 		 		 		 -	
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Table 10 Significance values for Emax values of drugs in Table 8. Analysis of variance followed by Bonferroni’s post-
hoc test was performed to determine whether there were any significant differences between the receptors for the 
indicated drug. 
 
Emax	
	       		 MOR-TR	 MOR-1	 MOR-1A	 MOR-1B	 MOR-1C	 MOR-1E	 MOR-1O	
DAMGO	 		 		 		 		 		 		 		
MOR-TR	 -	 NS	 NS	 NS	 NS	 NS	 NS	
MOR-1	 		 -	 NS	 NS	 NS	 NS	 NS	
MOR-1A	 		 		 -	 NS	 NS	 NS	 NS	
MOR-1B	 		 		 		 -	 NS	 NS	 NS	
MOR-1C	 		 		 		 		 -	 NS	 NS	
MOR-1E	 		 		 		 		 		 -	 NS	
MOR-1O	 		 		 		 		 		 		 -	
	        Emax	
	       		 MOR-TR	 MOR-1	 MOR-1A	 MOR-1B	 MOR-1C	 MOR-1E	 MOR-1O	
Morphine	 		 		 		 		 		 		 		
MOR-TR	 -	 P	≤	0.0001	 P	≤	0.0001	 P	≤	0.0001	 P	≤	0.0001	 P	≤	0.001	 P	≤	0.001	
MOR-1	 		 -	 NS	 NS	 NS	 P	≤	0.001	 P	≤	0.01	
MOR-1A	 		 		 -	 NS	 NS	 P	≤	0.001	 P	≤	0.01	
MOR-1B	 		 		 		 -	 NS	 P	≤	0.05	 NS	
MOR-1C	 		 		 		 		 -	 P	≤	0.01	 NS	
MOR-1E	 		 		 		 		 		 -	 NS	
MOR-1O	 		 		 		 		 		 		 -	
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Table 10 continued. Significance values for Emax values of drugs in Table 8. Analysis of variance followed by 
Bonferroni’s post-hoc test was performed to determine whether there were any significant differences between the 
receptors for the indicated drug. 
 
Emax	
	       		 MOR-TR	 MOR-1	 MOR-1A	 MOR-1B	 MOR-1C	 MOR-1E	 MOR-1O	
b-Endorphin	 		 		 		 		 		 		 		
MOR-TR	 -	 NS	 NS	 NS	 NS	 NS	 NS	
MOR-1	 		 -	 NS	 NS	 NS	 NS	 NS	
MOR-1A	 		 		 -	 NS	 NS	 NS	 NS	
MOR-1B	 		 		 		 -	 NS	 NS	 NS	
MOR-1C	 		 		 		 		 -	 NS	 NS	
MOR-1E	 		 		 		 		 		 -	 NS	
MOR-1O	 		 		 		 		 		 		 -	
	        Emax	
	       		 MOR-TR	 MOR-1	 MOR-1A	 MOR-1B	 MOR-1C	 MOR-1E	 MOR-1O	
Endomorphin	1	 		 		 		 		 		 		 		
MOR-TR	 -	 NS	 P	≤	0.001	 NS	 NS	 NS	 NS	
MOR-1	 		 -	 P	≤	0.001	 NS	 NS	 NS	 NS	
MOR-1A	 		 		 -	 NS	 P	≤	0.01	 P	≤	0.01	 P	≤	0.05	
MOR-1B	 		 		 		 -	 NS	 NS	 NS	
MOR-1C	 		 		 		 		 -	 NS	 NS	
MOR-1E	 		 		 		 		 		 -	 NS	
MOR-1O	 		 		 		 		 		 		 -	
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Table 10 continued. Significance values for Emax values of drugs in Table 8. Analysis of variance followed by 
Bonferroni’s post-hoc test was performed to determine whether there were any significant differences between the 
receptors for the indicated drug. 
 
Emax	
	       		 MOR-TR	 MOR-1	 MOR-1A	 MOR-1B	 MOR-1C	 MOR-1E	 MOR-1O	
Endomorphin	2	 		 		 		 		 		 		 		
MOR-TR	 -	 NS	 NS	 NS	 NS	 NS	 NS	
MOR-1	 		 -	 NS	 NS	 NS	 NS	 NS	
MOR-1A	 		 		 -	 NS	 P	≤	0.05	 NS	 NS	
MOR-1B	 		 		 		 -	 NS	 NS	 NS	
MOR-1C	 		 		 		 		 -	 NS	 P	≤	0.05	
MOR-1E	 		 		 		 		 		 -	 NS	
MOR-1O	 		 		 		 		 		 		 -	
	        Emax	
	       		 MOR-TR	 MOR-1	 MOR-1A	 MOR-1B	 MOR-1C	 MOR-1E	 MOR-1O	
Met-Enk-Arg-Phe	 		 		 		 		 		 		 		
MOR-TR	 -	 NS	 NS	 NS	 P	≤	0.01	 NS	 NS	
MOR-1	 		 -	 NS	 NS	 P	≤	0.001	 NS	 NS	
MOR-1A	 		 		 -	 NS	 P	≤	0.05	 NS	 NS	
MOR-1B	 		 		 		 -	 P	≤	0.01	 NS	 NS	
MOR-1C	 		 		 		 		 -	 P	≤	0.01	 P	≤	0.001	
MOR-1E	 		 		 		 		 		 -	 NS	
MOR-1O	 		 		 		 		 		 		 -	
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Table 10 continued. Significance values for Emax values of drugs in Table 8. Analysis of variance followed by 
Bonferroni’s post-hoc test was performed to determine whether there were any significant differences between the 
receptors for the indicated drug. 
 
Emax	
	       		 MOR-TR	 MOR-1	 MOR-1A	 MOR-1B	 MOR-1C	 MOR-1E	 MOR-1O	
Methadone	 		 		 		 		 		 		 		
MOR-TR	 -	 P	≤	0.0001	 P	≤	0.0001	 P	≤	0.0001	 P	≤	0.0001	 P	≤	0.0001	 P	≤	0.0001	
MOR-1	 		 -	 NS	 NS	 NS	 NS	 NS	
MOR-1A	 		 		 -	 NS	 NS	 NS	 NS	
MOR-1B	 		 		 		 -	 NS	 NS	 NS	
MOR-1C	 		 		 		 		 -	 NS	 NS	
MOR-1E	 		 		 		 		 		 -	 NS	
MOR-1O	 		 		 		 		 		 		 -	
	        Emax	
	       		 MOR-TR	 MOR-1	 MOR-1A	 MOR-1B	 MOR-1C	 MOR-1E	 MOR-1O	
Fentanyl	 		 		 		 		 		 		 		
MOR-TR	 -	 NS	 NS	 NS	 NS	 NS	 NS	
MOR-1	 		 -	 NS	 NS	 NS	 NS	 NS	
MOR-1A	 		 		 -	 NS	 NS	 NS	 NS	
MOR-1B	 		 		 		 -	 P	≤	0.05	 NS	 NS	
MOR-1C	 		 		 		 		 -	 NS	 NS	
MOR-1E	 		 		 		 		 		 -	 NS	
MOR-1O	 		 		 		 		 		 		 -	
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Part III – C-terminal splice variants differ in their inherent 
signaling bias and impact agonist induced therapeutic and side 
effects in-vivo 
 
β-arrestins are essential for the internalization of the receptor and act 
as scaffolds for the activation of several downstream effects ranging 
from desensitization, downregulation, as well as resensitization of the 
receptor. The functional relevance of β-arrestins has been vigorously 
explored in the opioid field. A β-arrestin-1 knockout animal is 
developmentally normal and exhibits normal cardiac parameters. 
However, the stimulation of the β-adrenergic receptor in this animal 
produces an exaggerated hemodynamic response (Conner et al., 1997). 
This indicates that β-arrestin-1 plays a role in cardiac β-adrenergic 
receptor desensitization.  
 
Bohn et al. used a β-arrestin-2 knockout animal model to understand 
its relevance in GPCR function in vivo. β-arrestin-2 knockout mice 
show prolonged morphine analgesia and develop no tolerance in 
response to acute or chronic morphine treatment (Bohn et al., 1999; 
Bohn et al., 2000). As shown in Figure 20, wild-type mice exhibited a 
roughly 50% reduction in morphine responsiveness if they received 
morphine, as compared to saline, the day before. Whereas, the barr2-/- 
mice maintained the same degree of responsiveness to morphine, 
regardless of if they had been treated with saline or morphine on the 
previous day. This indicates that the barr2-/- mice do not develop 
acute antinociceptive tolerance to morphine.  
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Figure 20 Lack of morphine antinociceptive tolerance in barr2-/- mice.  
A. Paw withdrawal latency after a moderate dose of morphine (10mg per kg, 
subcutaneously (s.c.) 24h after receiving an injection of either saline or 100 
mg per kg morphine. B. Paw withdrawal latency after daily administration of 
morphine. C. Dose response curve comparing morphine induced analgesia 
from day 1 to day 9. (From Bohn et al., 1999) 
 
They also looked at analgesia after chronic morphine treatment, as in 
the clinical setting, tolerance to morphine's analgesic properties 
usually develops over continued use of moderate levels of the drug. 
Mice were injected daily with morphine, and paw-withdrawal latencies 
were recorded (Fig. 20b). Although the wild-type littermates had 
significantly diminished responsiveness to the drug by day 5, the 
knockout mice continued to experience as much antinociception on 
A B 
C 
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day 5 to day 9 as on day 1. Notably, the barr2-/- mice did not 
experience a shift in their sensitivity to morphine after chronic daily 
administration, whereas the wild-type mice experienced a significant 
rightward shift in efficacy after continued treatment (Fig. 20c). In 
addition, these mice showed no significant difference in comparison to 
wild type mice in their naloxone induced withdrawal. This was in 
agreement with earlier studies that have linked physical dependence to 
a cAMP (G protein pathway) mediated response. 
  
These findings are critical because they link the functional significance 
of β-arrestin-2 knockdown to prolonged analgesia and tolerance. 
Consequently, drugs that are endogenously G protein biased as 
against β-arrestin-2 biased would presumably lead to a more effective 
analgesic response with limited tolerance side effects. A critical 
dilemma facing our efforts to discover further examples of β-arrestin 
biased ligands is how best to detect and quantify bias. In practice, 
ligand bias is defined operationally by the methods used to 
characterize receptor functions. For G-protein function, there are 
many well-established assays with high sensitivity and specificity, and 
robust high throughput systems are available for any 7TMR of 
interest. However, there are far fewer methods for assessing β-arrestin 
efficacy. These include measurements of receptor phosphorylation, β-
arrestin translocation to receptors and β-arrestin functions. Measures 
of β-arrestin functions include receptor desensitization and 
internalization and β-arrestin-dependent signals such as ERK1/2 
activation. Receptor desensitization and internalization can be difficult 
 119 
to interpret because these effects can occur through both β-arrestin 
dependent and β-arrestin independent mechanisms. Similarly, 
ERK1/2 activation can occur through many pathways, necessitating 
careful controls to ensure reliable measurement of β-arrestin signals. 
Thus, the simplest assays of β-arrestin efficacy are measures of β-
arrestin translocation to receptors. 
 
Much of the recent work in the opioid field has focused on ligand bias 
at the MOR-1 receptor. However, the inherent endogenous bias of a 
drug would be the summation of its biases across the different µ-OR 
variants. The differences in receptor biases among the splice variants 
of the mu receptor is a previously unexplored subject. Here, we have 
tried to calculate signal bias across 6 C-terminal splice variants 
mMOR-1-PK, mMOR-1A-PK, mMOR-1B1-PK, mMOR-1C-PK, mMOR-
1E-PK, mMOR-1O-PK and compare how it varies from the control 
receptor mMOR-TR-PK. We looked at the β-arrestin-2 pathway using 
DiscoverX PathHunter system and G protein using [35S]GTPγS binding 
assay as described in Part I and II. 
 
We chose to use the operational model of Black and Leff to quantify 
the effective signaling by receptors. To compare the relative activity of 
agonists in the two pathways and identify the bias, we generated 
concentration response curve for each signaling pathway (Figure 21 –
27). As described in methods, we then compared the log(τ/Ka) value of 
each test ligand to the log(τ/Ka) of a reference ligand, like DAMGO, for 
both G protein activation and arrestin recruitment. We used a 
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reference ligand that has a very similar EC50 value for both the G 
protein and arrestin pathways and displays full efficacy at both 
pathways. Ligand bias is quantified by comparing the relative activity 
of an agonist in one assay to the relative activity in another assay, 
using the same reference ligand. This method reduces to the 
observation or the system bias (Kenakin et al., 2013). Transduction 
coefficients are useful in comparing the relative signaling of ligands, 
but can be problematic when trying to measure the efficacy of agonists 
that produce maximal or no effect in a given signaling pathway, like 
Buprenorphine (Rajagopal, 2013). Due to the limitations of this 
method, we were not able to quantify bias for Buprenorphine, even 
though, it is a perfectly β-arrestin biased agonist in our hands that 
does not recruit β-arrestin at any of the C-terminal splice variants. 
 
After calculating the bias factors using the Black and Leff Operational 
Model, we used a few different normalization methods to compare 
differences across variants or across drugs at one variant. We 
generated a heat map of biased factors (Table 11).  The negative (blue) 
values indicate arrestin bias whereas the positive bias (red) values 
indicate G protein bias. Table 11a is normalized with respect to 
DAMGO at every variant and is optimized to compare differences 
across drugs at a variant. As a proof of concept, we see that the 
peptides like Endomorphin1 and Endomorphin2 are arrestin biased at 
mMOR-1, as has been published previously (Rivero et al., 2012). Met-
Enk-Arg-Phe is significantly G protein biased at several of the C-
terminal splice variants. It can be observed that at each variant,  
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Figure 21 DAMGO induced β-arrestin2 recruitment and G protein activation 
in CHO cells stably transfected with variants A. MOR-TR-PK B. MOR-1-PK C. 
MOR-1A-PK D. MOR-1B1-PK E. MOR-1C-PK F. MOR-1E-PK G. MOR-1O-PK 
β-arrestin2 recruitment and G protein activation. A PathHunter β-arrestin2 
assay (DiscoverX) and [35S]GTPγS binding assay were performed, as described 
in Methods. Results are from three independent experiments. Each dose 
response curve has been normalized to maximal DAMGO stimulation (10µM 
DAMGO) at the particular receptor variant for comparison across drugs.  
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Figure 22 Morphine induced β-arrestin2 recruitment and G protein activation 
in CHO cells stably transfected with variants A. MOR-TR-PK B. MOR-1-PK  
C. MOR-1A-PK D. MOR-1B1-PK E. MOR-1C-PK F. MOR-1E-PK G. MOR-1O-
PK β-arrestin2 recruitment and G protein activation. A PathHunter β-
arrestin2 assay (DiscoverX) and [35S]GTPγS binding assay were performed, as 
described in Methods. Results are from three independent experiments. Each 
dose response curve has been normalized to maximal DAMGO stimulation 
(10µM DAMGO) at the particular receptor variant for comparison across 
drugs.  
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Figure 23 b-Endorphin induced β-arrestin2 recruitment and G protein activation 
in CHO cells stably transfected with variants A. MOR-TR-PK B. MOR-1-PK C. 
MOR-1A-PK D. MOR-1B1-PK E. MOR-1C-PK F. MOR-1E-PK G. MOR-1O-PK β-
arrestin2 recruitment and G protein activation. A PathHunter β-arrestin2 assay 
(DiscoverX) and [35S]GTPγS binding assay were performed, as described in 
Methods. Results are from three independent experiments. Each dose response 
curve has been normalized to maximal DAMGO stimulation (10µM DAMGO) at 
the particular receptor variant for comparison across drugs.  
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Figure 24 Endomorphin1 induced β-arrestin2 recruitment and G protein activation 
in CHO cells stably transfected with variants A. MOR-TR-PK B. MOR-1-PK C. MOR-
1A-PK D. MOR-1B1-PK E. MOR-1C-PK F. MOR-1E-PK G. MOR-1O-PK β-arrestin2 
recruitment and G protein activation. A PathHunter β-arrestin2 assay (DiscoverX) 
and [35S]GTPγS binding assay were performed, as described in Methods. Results 
are from three independent experiments. Each dose response curve has been 
normalized to maximal DAMGO stimulation (10µM DAMGO) at the particular 
receptor variant for comparison across drugs 
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Figure 25 Endomorphin2 induced β-arrestin2 recruitment and G protein activation 
in CHO cells stably transfected with variants A. MOR-TR-PK B. MOR-1-PK C. MOR-
1A-PK D. MOR-1B1-PK E. MOR-1C-PK F. MOR-1E-PK G. MOR-1O-PK β-arrestin2 
recruitment and G protein activation. A PathHunter β-arrestin2 assay (DiscoverX) 
and [35S]GTPγS binding assay were performed, as described in Methods. Results 
are from three independent experiments. Each dose response curve has been 
normalized to maximal DAMGO stimulation (10µM DAMGO) at the particular 
receptor variant for comparison across drugs 
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Figure 26 Met-Enk-Arg-Phe induced β-arrestin2 recruitment and G protein activation 
in CHO cells stably transfected with variants A. MOR-TR-PK B. MOR-1-PK C. MOR-
1A-PK D. MOR-1B1-PK E. MOR-1C-PK F. MOR-1E-PK G. MOR-1O-PK β-arrestin2 
recruitment and G protein activation. A PathHunter β-arrestin2 assay (DiscoverX) and 
[35S]GTPγS binding assay were performed, as described in Methods. Results are from 
three independent experiments. Each dose response curve has been normalized to 
maximal DAMGO stimulation (10µM DAMGO) at the particular receptor variant for 
comparison across drugs 
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Figure 27 Methadone induced β-arrestin2 recruitment and G protein 
activation in CHO cells stably transfected with variants A. MOR-TR-PK B. 
MOR-1-PK C. MOR-1A-PK D. MOR-1B1-PK E. MOR-1C-PK F. MOR-1E-PK 
G. MOR-1O-PK β-arrestin2 recruitment and G protein activation. A 
PathHunter β-arrestin2 assay (DiscoverX) and [35S]GTPγS binding assay 
were performed, as described in Methods. Results are from three 
independent experiments. Each dose response curve has been normalized to 
maximal DAMGO stimulation (10µM DAMGO) at the particular receptor 
variant for comparison across drugs 
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Figure 28 Fentanyl induced β-arrestin2 recruitment and G protein activation 
in CHO cells stably transfected with variants A. MOR-TR-PK B. MOR-1-PK C. 
MOR-1A-PK D. MOR-1B1-PK E. MOR-1C-PK F. MOR-1E-PK G. MOR-1O-PK β-
arrestin2 recruitment and G protein activation. A PathHunter β-arrestin2 
assay (DiscoverX) and [35S]GTPγS binding assay were performed, as described 
in Methods. Results are from three independent experiments. Each dose 
response curve has been normalized to maximal DAMGO stimulation (10µM 
DAMGO) at the particular receptor variant for comparison across drugs 
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Figure 29 Buprenorphine induced β-arrestin2 recruitment and G protein 
activation in CHO cells stably transfected with variants A. MOR-TR-PK B. 
MOR-1-PK C. MOR-1A-PK D. MOR-1B1-PK E. MOR-1C-PK F. MOR-1E-PK G. 
MOR-1O-PK β-arrestin2 recruitment and G protein activation. A PathHunter 
β-arrestin2 assay (DiscoverX) and [35S]GTPγS binding assay were performed, 
as described in Methods. Results are from three independent experiments. 
Each dose response curve has been normalized to maximal DAMGO 
stimulation (10µM DAMGO) at the particular receptor variant for comparison 
across drugs  
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Table 11 Heat map of biased factors. Biased factors were calculated using the Black and Leff Operational Model by 
using different normalization methods. Results are the mean ± S.E. of at least three independent experiments.A. 
normalized with respect to DAMGO at the variant for a comparison across drugs B. normalized with respect to every 
individual drug at mMOR-TR for a comparison across variants C. normalized with respect to drug in mMOR-1 for 
another comparison across variants D. normalized with respect to DAMGO at MOR-1 for a simultaneous comparison 
between drugs and variants.  
 
 
A. Normalized to DAMGO at the variant 
      MOR-TR MOR-1 MOR-1A MOR-1B1 MOR-1C MOR-1E MOR-1O 
DAMGO 1.0 1.0 1.0 1.0 1.0 1.0 1.0 
Morphine 2.8 -1.5 1.2 -1.2 1.5 -11.9 2.1 
b-Endorphin -17.9 -2.1 1.0 1.4 1.5 1.1 1.1 
Endomorphin2 -2.1 -4.5 -1.1 -2.7 -2.9 -6.5 2.5 
Endomorphin1 -4.6 -3.3 1.3 -2.3 -2.5 -1.4 -1.9 
Met-Enk-Arg-Phe -3.2 3.1 15.0 20.0 40.8 15.7 5.2 
Methadone 3.4 2.1 2.5 -1.9 -9.4 1.8 1.7 
Fentanyl -4.2 -4.4 -2.5 -6.0 -5.1 -3.0 -4.3 
        B. Normalized to drug in MOR -TR 
       MOR-TR MOR-1 MOR-1A MOR-1B1 MOR-1C MOR-1E MOR-1O 
DAMGO 1.0 3.1 1.6 -1.1 1.5 4.8 -3.3 
Morphine 1.0 -1.4 -1.5 -3.9 -1.2 -6.9 -6.3 
b-Endorphin 1.0 25.6 28.8 22.6 40.6 95.9 6.0 
Endomorphin2 1.0 1.4 3.0 -1.5 1.1 1.6 1.6 
Endomorphin1 1.0 4.3 9.4 1.7 2.8 30.7 -1.4 
Met-Enk-Arg-Phe 1.0 29.7 74.1 55.2 197.7 236.6 4.9 
Methadone 1.0 1.9 1.2 -7.1 -20.4 2.6 -6.6 
Fentanyl 1.0 2.9 2.6 -1.6 1.3 6.8 -3.5 
Bias	Factor 
Arrestin G-protein 
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C. Normalized to drug in MOR-1 
       MOR-TR MOR-1 MOR-1A MOR-1B1 MOR-1C MOR-1E MOR-1O 
DAMGO -3.1 1.0 -1.9 -3.5 -2.0 1.6 -10.2 
Morphine 1.4 1.0 -1.1 -2.8 1.2 -5.0 -3.3 
b-Endorphin -25.6 1.0 1.1 -1.1 1.6 3.7 -4.3 
Endomorphin2 -1.4 1.0 2.1 -2.1 -1.3 1.1 1.1 
Endomorphin1 -4.3 1.0 2.2 -2.5 -1.5 3.7 -6.0 
Met-Enk-Arg-Phe -29.7 1.0 2.5 1.9 6.7 8.0 -6.1 
Methadone -1.9 1.0 -1.6 -13.4 -38.5 1.4 -12.4 
Fentanyl -2.9 1.0 -1.1 -4.7 -2.3 2.3 -10.0 
        D. Normalized to MOR-1 DAMGO 
       MOR-TR MOR-1 MOR-1A MOR-1B1 MOR-1C MOR-1E MOR-1O 
DAMGO -3.1 1.0 -1.9 -3.5 -2.0 1.6 -10.2 
Morphine -1.1 -1.5 -1.7 -4.3 -1.3 -7.6 -5.0 
b-Endorphin -54.8 -2.1 -1.9 -2.4 -1.4 1.7 -9.2 
Endomorphin2 -6.5 -4.5 -2.2 -9.5 -5.7 -4.1 -4.1 
Endomorphin1 -14.0 -3.3 -1.5 -8.1 -4.9 1.1 -19.4 
Met-Enk-Arg-Phe -9.6 3.1 7.7 5.7 20.5 24.5 -2.0 
Methadone 1.1 2.1 1.3 -6.5 -18.6 2.9 -6.0 
Fentanyl -12.8 -4.4 -4.9 -21.0 -10.2 -1.9 -44.3 
Bias	Factor 
Arrestin G-protein 
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different drugs show different degrees of bias.  
 
Variants containing exon 7, like MOR-1C and MOR-1O have a higher 
propensity for β-arrestin2 bias. Table 11b and 11c are optimized to  
compare differences in biases across variants, and we observed that 
the mMOR-1O variant demonstrated an inherent and consistent β-
arrestin-2 bias across different drugs at the receptor. These findings 
can be significant since β-arrestin-2 has been previously linked with 
prolonged analgesic response along with no tolerance side effects. 
 
Calculating bias and using the different normalization methods gave 
us several additional insights into understanding the differences 
across these variants. When we looked at morphine activity, it was 
relatively unbiased with respect to DAMGO at all the variants except 
for at mMOR-1E where it was significantly β-arrestin biased. This is 
interesting because Koch et al. have looked at levels of 
phosphorylation in response to morphine across the different variants 
and observed high levels of phosphorylation at the mMOR-1E receptor 
after morphine treatment (Koch et al., 2001). Mu Opiod action is 
dependent on both biased signaling as well as the splice variant 
mediating the function. 
 
It also appears that the removal of 12 amino acids encoded by exon 4 
shifts the receptor to a β-arrestin bias (Table 11C, 11D). The mMOR-
TR response seems much similar to mMOR-1O, in that they are both 
arrestin biased relative to mMOR-1. Out of all the drug we tested, 
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methadone and fentanyl showed the most difference across the 
variants. When normalized to mMOR-1, Fentanyl was relatively 
unbiased at mMOR-1A, mMOR-1C and mMOR-1E, but significantly 
arrestin biased at mMOR-1O (10 fold). Methadone was unbiased at 
MOR-1A and MOR-1E but significantly arrestin biased at MOR-1C (38 
fold) and MOR-1O (12 fold).). This was the highest difference we saw 
across all drugs. 
 
These results are crucial in providing some indication of how these 
drugs would behave endogenously. These results become more 
significant when comparing the functional significance of alternative 
Figure 30 Schematic of the stop codon insertion on variant mRNAs. Three 
targeted mouse models, mE3M, mE4M and mE7M, were generated by 
inserting a stop codon at an appropriate site within indicated exons 
shown by colored boxes. Inserted and original stop codon are indicated by 
yellow and pink bars, respectively. In mE3M, a stop codon was inserted at 
the end of exon 3 to eliminate every C-terminal tails of all 7-TM and 6-TM 
variants, as well as 1-TM mMOR-1S. In mE4M and mE7M, a stop codon 
was created at the beginning of exon 4 or exon 7 to eliminate individual C-
terminal tails encoded by exon 4 or exon 7 of indicated variants, 
respectively. 
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C-termini in-vivo. In our lab, we have generated three mutant mouse 
models with truncations of the distal end of the C-terminus in two 
different inbred strains (Work done by Jin Xu and Ying Xian Pan). By 
truncating either all C-terminal tails or selectively truncating C-
terminal tails encoded by exon 4 or exon 7, we were able to show the 
importance of these C-terminal tails in morphine tolerance and 
physical dependence, and suggest a mechanism involving interactions 
between E7-encoded C-terminus and β-arrestin-2 for morphine-
induced desensitization and tolerance. The first mouse model (mE3M) 
was generated by inserting a stop codon at the 3’-end of exon 3 that 
prevents translation of all exons downstream of exon 3, even though 
their mRNAs are expressed. Thus, the mE3M homozygous mice 
express only truncated mu opioid receptors lacking any of distal C-
terminal tails. In the other two mouse models (mE4M and mE7M), we 
introduced a stop codon at the 5’-end of exon 4 (E4) and exon 7 (E7) to 
stop translation at the end of exon 3 only in those specific variants 
containing exon 4 or exon 7 in mE4M or mE7M mice, respectively 
(Figure 30). Based on our results from the in-vitro assays, we were 
most interested in the mE4M and mE7M mutant mice as they seem to 
have opposing effects on the receptor’s ability to recruit β-arrestin-2. 
 
As shown in Figure 31A, chronic morphine treatment (10mg/kg, twice 
a day) induced modest tolerance in the respective WT B6 control mice 
from all mutant mouse models over 5 days. However, in mE3M-B6 and 
mE4M-B6 homozygous mice, tolerance developed faster and to a 
greater extent. This enhanced tolerance was even more evident in  
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Figure 31 Effect of the C-terminal truncation on morphine tolerance. (A) 
Morphine tolerance in the mutant mice. Tolerance was induced and assessed 
as described in Methods. The number of mice used were: mE3M-B6, WT 
(+/+): 15 & homozygous (-/-): 14 in two independent experiments; mE4M-B6, 
+/+: 18 & -/-: 17 in two independent experiments; mE7M-B6, +/+: 20 & -/-: 
19 in three independent experiments; mE3M-129, +/+: 15 & -/-: 11 in two 
independent experiments; mE4M-129, +/+ & -/-: 13 in two independent 
experiments; mE7M-129, +/+ & -/-: 7 in one experiment. *: p < 0.05; ***: p < 
0.001; ****: p < 0.0001 (2-way ANOVA with Bonferroni’s post hoc test). (B) 
Morphine dose-response curve in the mutant mice. Cumulative dose-
response studies were performed before (Day 1) and after (Day 5) morphine 
treatment (C) Antisense vivo-morpholino oligo (ANT-vMO targeting intron/E7) 
study in CD-1 mice. Top: mRNA expression.  RNAs from the PAG dissected 
on Day 6 (see bottom panel) were used in RT-qPCRs. MIS-vMO: mismatched 
oligo; All 2-(ΔCt) values are normalized with Saline group. Results are the mean 
± SEM of at least three individual samples. *: p < 0.05; **: p < 0.01(1-way 
ANOVA with Bonferroni’s post hoc test).  Bottom: Morphine tolerance. Group 
of mice were i.c.v. injected with 10 µg of ANT-vMO (n = 18) or MIS-vMO (n = 
16), or Saline (n = 19), for four days (Days 1 – 4). Tolerance was induced by 
twice-daily morphine injection (10 mg/kg, s.c.) for 5 days (Days 2 – 6). 
Morphine analgesia was tested on Days 1, 4 and 6. Results are from two 
independent experiments. 2-way ANOVA with Bonferroni’s post hoc test was 
used. # & @: compared to Saline and MIS-vMO, p < 0.0001, respectively. *: 
compared to MIS-vMO, p < 0.05.   
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Figure 32 Effect of the C-terminal truncation on morphine physical 
dependence in the mutant mice. (A) Morphine physical dependence. 
Morphine physical dependence was assessed by naloxone-precipitated 
withdrawal after chronic morphine treatment in the mutant mice in B6 (Top) 
or 129 (Bottom) backgrounds. Results were showed as the number of jumps 
within 15 min immediately followed naloxone injection. The number of mice 
used were: mE3M-B6, WT (+/+): 15 & homozygous (-/-): 14 in two 
independent experiments; mE4M-B6, +/+: 18 & -/-: 17 in two independent 
experiments; mE7M-B6, +/+ & -/-: 10 in one independent experiments; 
mE3M-129, +/+: 15 & -/-: 11 in two independent experiments; mE4M-129, 
+/+ & -/-: 13 in two independent experiments; mE7M-129, +/+ & -/-: 7 in 
one experiment. 1-way ANOVA with Bonferroni’s post hoc test was used. 
Compared to +/+, *: p < 0.05; #: p < 0.0001. +/+: WT mice; -/-: homozygous 
mice 
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mE3M and mE4M homozygous mice on the 129 background. In 
contrast to the minimal morphine tolerance in the WT 129 mice over 
the same time period, both mE3M-129 and mE4M-129 homozygous 
mice developed modest morphine tolerance similar to that seen in the 
WT B6 mice. mE3M-129 and mE4M-129 homozygous mice, however, 
developed modest morphine tolerance similar to that seen in the WT 
B6 mice. Cumulative dose response curve studies before and after 
chronic morphine administration also gave the same result where 
chronic morphine significantly shifted the curves to the right with a 
higher ED50 value in both mE3M-129 and mE4M-129 homozygous 
mice (Figure 31B). This is consistent with our earlier findings in in-
vitro assays, where removal of the 2 amino acids encoded by exon 4 
pushed the receptor to a more arrestin recruiting state. 
 
Interestingly, truncating exon 7 (E7)-encoded C-terminal tails in B6 
(mE7M-B6 homozygous) mice had an opposite effect. There was little 
decrease in morphine responses over 5 days compared to the WT B6 
littermate controls and the cumulative dose response studies revealed 
only a slight shift to the right in mE7M-B6 homozygous mice following 
chronic morphine (2.2-fold) compared to a far greater shift in WT B6 
control mice (5.2-fold).  
 
To further investigate the function of exon 7-associated C-terminal 
variants in morphine tolerance and dependence, we used a knockdown 
strategy with an antisense vivo-morpholino oligo that targets 
intron/exon 7 to block splicing from exon 3 (E3) to exon 7 (E7), 
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eliminating E7-containing transcripts. Mice treated with saline or mis-
morpholigo oligo displayed normal morphine tolerance after 5-day 
morphine treatment. As expected, mice treated with the antisense 
vivo-morpholino oligo showed little morphine tolerance. These results 
are similar to those in mE7M-B6 homozygous mice, confirming the 
involvement of exon 7-associated variants in morphine tolerance. Not 
surprisingly, if the exon 7 variants are indeed the β-arrestin-2 biased 
variants, knocking out these mutants would give a phenotype similar 
to the Bohn et al. β-arrestin-2 knockout mice. 
 
Morphine physical dependence was assessed with naloxone-
precipitated withdrawal following 5 days of chronic morphine 
treatment by measuring jumping, a reliable measure of the physical 
dependence. Naloxone precipitated significantly less jumping in both 
mE3M-B6 and mE4M-B6 homozygous mice than their WT B6 control 
mice (Top panel, Figure 32A), suggesting a diminished level of 
dependence.  There was no significant difference in the jumping 
frequency between the mE7M-B6 WT and homozygous mice. These 
results suggest that unlike morphine tolerance, morphine dependence 
is not influenced by exon 7-associated variants in B6 or CD-1 mice.  
The WT 129 control mice all showed lower jumping frequencies than 
the WT B6 control mice (Bottom panel, Figure 32A), consistent with 
previous observations (Bohn et al., 1999). However, we observed even 
fewer jumps in E3M-B6 129 homozygous mice.  As in the B6 
background, the exon 7 truncation in the 129 mice showed no change 
in jumping, again supporting the hypothesis that knocking out the 
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exon 7 variants gives a phenotype similar to the β-arrestin-2 knockout 
mice.   
 
These findings serve to validate our results from the in-vitro assays 
where we were able to show the MOR-1O receptor variant was 
relatively more β-arrestin-2 biased. When knocking down this variant, 
as in the mE7M model, these mice show a phenotype similar to the β-
arrestin-2 knockout mice as shown by Bohn et al. This suggests a 
physical and functional association of E7-encoded C-terminal tails 
with β-arrestin-2. One caveat with this interpretation is that mE7M 
model also affects 2 other 7TM receptor variants MOR-1C and MOR-
1U, as well as a 6TM variant, MOR-1M. Our follow up study should 
look at the signaling bias at these other variants in trying to 
understand the specific moiety in the C-tail that encourages the 
receptor interaction with β-arrestin-2. 
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Chapter IV – Discussion 
 
The C-terminal tail is the intracellular part of the receptor that 
interacts with other proteins and signaling complexes to trigger 
downstream signaling pathways. Alternative splicing of the 
cytoplasmic tail has been observed for a number of G protein-coupled 
receptors including the sst2A somatostatin receptor (Vanetti et al., 
1992), the D2 dopamine receptor (Guiramand et al., 1995), the EP3 
prostaglandin receptor (Namba et al., 1993), and a number of 
serotonin receptor subtypes (Lucas et al., 1995). C-terminal splicing is 
thought to modulate several aspects of G protein coupled receptor 
physiology, like cell and tissue-specific expression, subcellular 
targeting, coupling to specific G proteins as well as β-arrestin 
recruitment. 
 
The µ-OR shows extensive alternative splicing. Over the years, more 
than 60 splice variants have been isolated (Pasternak and Pan, 2013). 
These receptor variants show a lot of heterogeneity in their expression 
pattern in the brain, their localization in the cell (pre- vs post-
synaptic), their phosphorylation as well as internalization pattern. The 
µ-OR variants have been detected in different regions of rodent brain 
at the protein level, immunohistochemically and by Western blot, and 
at the mRNA level using RT-PCR (Abbadie et al., 2000a,b, 2001; Pan et 
al., 1999, 2000, 2001, 2003). Antisense mapping studies have 
constantly implicated that all the variants are functionally relevant 
(Pan et al., 1999, 2000, 2001). 
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In this report, we have demonstrated for the first time that the C-
terminal splice variants of the µ-OR show differences in their signaling 
bias. Until recently, a drug’s efficacy for β-arrestin recruitment was 
believed to be proportional to its efficacy for G-protein activities. This 
paradigm restricts 7TMR drug effects to a linear spectrum of 
responses, ranging from inhibition of all responses to stimulation of all 
responses. We tested 6 different C-terminal splice variants, mMOR-1, 
mMOR-1A, mMOR-1B1, mMOR-1C, mMOR-1E and mMOR-1O 
receptor and compared it to the control receptor mMOR-TR which is 
truncated at exon 3. Using the [35S]GTPγS and DiscoverX PathHunter 
assay, we were able to quantify agonist induced stimulation in these 
pathways across the different C-terminal variants and observe clear 
differences. One caveat of the DiscoverX PathHunter assay is that 
these constructs have an additional 4kDa prolink fragment at the C-
terminus. However, in spite of the limitations, the DiscoverX assay 
seemed a more reasonable choice in comparison to the other available 
assays TranslatorTM β-arrestin-GFP, TANGO or FRET assays for 
reading arrestin recruitment. These other assays involve a more 
substantive manipulation of the C-terminus in comparison to the 
DiscoverX assay and are relatively less high-throughput.  
 
All of these C-terminal splice variants are 7TM receptors that contain 
the same binding pocket. As expected, they have similar binding 
affinity for the different mu agonists. Despite the similar affinity for 
these agonists, the C-terminal variants are significantly different in 
their agonist induced effects. For example, in response to DAMGO, 
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mMOR-TR, mMOR-1C and mMOR-1O receptors are equi-effective as 
well as equi-potent in both the β-arrestin and [35S]GTPγS pathways. 
Whereas, some other variants, mMOR-1, mMOR-1A and mMOR-1E 
receptors show a right shift of the arrestin dose response curve. 
Morphine is a full agonist in the [35S]GTPγS assay across most C-
terminal variants, however, it is only a partial agonist in the β-arrestin 
assay. For b-Endorphin, the MOR-TR receptor was similarly effective 
and potent in both pathways which wasn’t true for any of the other C-
terminal variants.  
 
Agonists like Met-Enk-Arg-Phe and Methadone showed a lot of 
variability in their response at the different receptor variants. Both 
these agonists were more effective in the β-arrestin recruitment assay 
in comparison to the [35S]GTPγS at the control mMOR-TR receptor. 
Similar to the truncated receptor, mMOR-1A and mMOR-1C were also 
more effective in the β-arrestin pathway. However, in spite of the 
higher Emax, the mMOR-1A β-arrestin curve was significantly right 
shifted. For Methadone, mMOR-1B and mMOR-1O receptors were 
equi-effective and equi-potent in both the assays. But, mMOR-1 and 
mMOR-1C had a significant difference where the agonists were more 
effective than DAMGO in the [35S]GTPγS assay and acted as partial 
agonists (Emax ~50% DAMGO) in the β-arrestin recruitment assay.  
 
Calculating bias and using the different normalization methods gave 
us several additional insights into understanding the differences 
across these variants. At each variant, different drugs show different 
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degrees of bias. We saw that the peptides like Endomorphin1 and 
Endomorphin2 are arrestin biased at mMOR-1, as has been published 
previously (Rivero et al., 2012). We observed differences in both the 
magnitude of the bias as well as the directionality of the  bias across 
variants. Methadone was seen to be a mild G protein biased agonist as 
mMOR-1 (Bias factor 2.1) but was a strong arrestin biased agonist at 
mMOR-1C (Bias factor -9.4). Met-Enk-Arg-Phe was also a mild G 
protein biased agonist at mMOR-1 (Bias factor 3.1) but was a much 
stronger G protein biased agonist at mMOR-1C (Bias factor 41). This 
suggests that mu opioid action is dependent on both biased signaling 
and the splice variant mediating the function. 
 
When comparing mMOR-1 to the truncated receptor mMOR-TR, we 
also observed that the removal of 12 amino acids encoded by exon 4 
shifts the receptor to a β-arrestin-2 bias. These observations are 
critical because the truncated receptor, mMOR-TR contains exon 3 
which is shared by all C-terminal variants. As a result, the potential 
phosphorylation sites (Ser/ Thr residues like Ser375) present in the 
exon 3 region of the receptor are conserved across all of the receptor 
variants. Despite the availability of these conserved sites, the C-
terminal variants show differences in their β-arrestin recruitment 
pattern. This suggests that the addition of only a few amino acids, as 
in MOR-1A, can significantly impact the ability of the C-tail to interact 
with other kinases and signaling complexes leading to differences in 
signaling pattern and ultimately, signal bias. Furthermore, in addition 
to these conserved sites, some of the C-terminal splice variants may 
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have additional active phosphorylation sites downstream of exon 3. 
Exon 7 containing variants, like mMOR-1C and mMOR-1O, have 
several additional potential phosphorulation sites downstream of exon 
3 and were seen to have a higher propensity for β-arrestin-2 
recruitment. 
 
Mu agonist-induced receptor phosphorylation and subsequent β-
arrestin binding that restrains further coupling of the receptor with 
the G proteins has been postulated as one mechanism of receptor 
desensitization and mu opioid tolerance (Raehal et al., 2011; Willliams 
et al., 2013). Earlier studies have shown morphine to induce different 
levels of receptor phosphorylation, internalization and desensitization 
among several C-terminal splice variants, including the E4-associated 
mMOR-1 and E7-associated mMOR-1C in HEK293 cells (Koch et al., 
1998). mMOR-1C, but not mMOR-1, is internalized in vivo by 
morphine administration (Abbadie et al., 2001). Our in-vitro findings 
suggest differences in arrestin recruitment pattern across the C-
terminal variants. On quantification, we see that the mMOR-1O 
variant, which has an additional 30 amino acids from exon 7 
downstream of exon 3, is significantly β-arrestin biased relative to the 
other C-terminal variants. The exon 7 associated C-terminal tail has 
been postulated to have a number of additional phosphorylation sites 
for various protein kinases, such as GRKs (Figure 6), raising the 
hypothesis that E7-associated C-terminal variants favor morphine-
induced phosphorylation by GRKs, leading to increased β-arrestin 
recruitment and facilitated receptor desensitization.  
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In addition to the [35S]GTPγS assay, we also used pERK activation as a 
validation of our previous results and a further indication of the 
agonist induced bias. ERK activation can sometimes be inconclusive 
as the ERK activation can be a result of either G protein or β-arrestin 
activation. We used western blot analysis in another cell line, HEK 
cells, to test 2 of the C-terminal variants, MOR-1 and MOR-1O. The 
HEK cell lines expressing the receptor variants showed no significant 
differences in pERK activation after agonist treatment. This result 
serves as a validation of our results in the [35S]GTPγS assay because 
we used 3 different agonists at their equi-active [35S]GTPγS dose. In 
addition, it also suggests that the cytoplasmic pERK activation we are 
observing in a western blot assays is primarily coming from the G 
protein pathway. 
 
These findings, although significant, come with the caveat that these 
pathways have been studied in a system that is significantly 
dependent on the assay conditions, cell lines used, levels of other 
kinases and G proteins expressed in the system. Another limitation 
with our current method is that it studies one receptor in isolation 
from all the other receptor variants. While this is useful to study the 
individual receptor pharmacology, these receptors exist in a very 
heterogeneous fashion in the brain. Endogenously, different 
combination of receptor variants might be expressed in a cell. The 
expression of different receptor combinations might lead to different 
 146 
homo/ heterodimers, in which case, their signaling bias might be 
completely different than what we observe individually. 
 
Another caveat is the difference in signal amplification observed in the 
two assays. The [35S]GTPγS assay has a 1 : many signal amplification 
ratio, where one receptor can activate more than one G protein. 
However, the β-arrestin assay has a 1 : 1 signal amplification, such 
that one receptor can only recruit one β-arrestin-2 unit. Such 
differences in signal amplification, if not carefully monitored, can lead 
to false interpretation of bias as the receptors would seem more 
effective in the [35S]GTPγS assay.  
 
Our studies explored the difference in the mouse mu opioid receptor 
variants. This was done to facilitate further studies using mouse in-
vivo models. However, significant overlap has been shown between the 
mouse and the human receptor variants. With reference to our 
findings, both the mouse and the human mu receptor gene contain 
exon 4 with high consensus in their sequence. Both mouse and 
humans express the MOR-1O receptor variant. The MOR-1O receptor 
variant is encoded by exon 7ab in mouse and exon O in humans. Both 
the mouse and human receptor variants contain 30 amino acids 
downstream of exon 3 with significant overlap in the specific amino 
acid residues present at the tip of the C-tail. 
 
The predominant 7TM variant is MOR-1, which contains 12 exon 4-
encoded amino acids.  Removal of those 12 amino acids facilitated 
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morphine tolerance in mE4M homozygous mice on both B6 and 129 
backgrounds, implying that expression of the E4-encoded C-terminal 
sequences impedes the development of morphine tolerance.  In 
contrast, truncation of E7-associated C-terminal tails attenuated 
morphine tolerance, implying that those sequences facilitate the 
development of morphine tolerance. The importance of E7-associated 
variants was further supported by the antisense model where 
downregulation of the variants led to similar responses. Our in vitro 
observation suggest that several mu agonists stimulate β-arrestin2 
biased signaling relative to G protein coupling, with an E7-associated 
7TM variant, mMOR-1O in comparison to the E4-associated C-
terminal 7TM mMOR-1. This also provides a strong support for the 
functional interaction between the E7-associated C-terminal tails and 
β-arrestin-2. 
 
 
More interestingly, mE7M mice showed a phenotype similar to the β-
arrestin-2 KO mice. These mE7M mice had no substantial difference in 
analgesic sensitivity or physical dependence but developed no 
Figure 33 Comparison of behavioral and biochemical studies in targeted 
mice 
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tolerance. Similarity in several morphine-induced behaviors between 
these mE7M-B6 homozygous and β-arrestin-2 KO mice suggests a 
physical and functional association of E7-encoded C-terminal tails 
with β-arrestin-2, a hypothesis further supported by our in vitro data 
that several mu agonists displayed more bias toward arrestin binding 
on E7-associated variants, particularly mMOR-1O. Furthermore, the 
ability to modulate morphine tolerance by down-regulating the E7-
associated variants with an antisense vivo-morpholino oligo illustrated 
the therapeutic potential of targeting E7-associated variants.   
The in-vivo data shows that the distal C-terminal sequences 
significantly impacted morphine tolerance, with opposite effects seen 
between E4- and E7-associated C-terminal truncation models. Exon 4 
facilitates tolerance whereas, exon 7 diminishes tolerance. Similarity 
between the Exon 7 truncation and β-arrestin2 KO model confirms a 
physical and functional link between exon 7 containing variants and 
β-arrestin-2. The mE7 mice show a difference in their reward behavior 
in comparison to the β-arrestin2 KO studies by Bohn et al. These 
differences could be a result of the strain differences between the two 
models. β-arrestin2 KO mice from Bohn studies were on a mixed 
B6/129svj background.  
 
Additionally, the exon 7-encoded C-terminal sequences contain a 
consensus β-arrestin-2 binding motif, PxPxxE or PxxPxxE that 
interacts with positively charged residues at the N-terminus of β-
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arrestin-2, predicted mainly based on the recent crystal structure of 
rhodopsin-β-arrestin2 complex. It will be interesting to further explore 
the role of these phosphorylation or negatively charged sites on the 
E7-encoded C-terminal tail in β-arrestin-2 binding and receptor 
signaling.   
 
While these results clearly show the importance of individual C-
termini in morphine actions, attributing these actions to a specific 
variant is not yet possible since the current truncation model impacts 
on more than one variant. E4-associated C-terminal tails are present 
in the 7TM variants mMOR-1, mMOR-1H, mMOR-1i and mMOR-1J, 
and the 6TM variant mMOR-1G. E7-associated C-terminal tails are 
also present in the 7TM variants mMOR-1C, mMOR-1O and mMOR-
1U, as well as the 6TM variant mMOR-1M. We anticipate that since 
morphine has a far greater affinity for 7TM receptor in binding assays, 
it seems likely that the truncation phenotypes involve 7TM variants. 
Future experiments will be necessary to follow up on these other 
receptor variants and their signaling bias. 
 
The involvement of E7-associated C-terminal tails in promoting 
morphine tolerance raises the possibility that E7-associated C-
terminal variants may be potential targets for therapeutic intervention 
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to alleviate these morphine effects, as shown by our antisense vivo-
morpholino oligo study. This oligo markedly reduced E3/E7 splicing 
and expression of E7-associated variants and attenuated morphine 
tolerance without affecting morphine dependence, mimicking the effect 
of truncation of E7-associated C-terminal tails in mE7M-B6 
homozygous mice. Antisense morpholino oligos have been successfully 
used to correct aberrant splicing in a growing number of animal 
models for several human diseases. Our results provide another 
example where in vivo antisense morpholino approach might be of 
value one day clinically. In spite of the caveats of our approach, our 
findings establish that different C-terminal splice variants, through 
differences in biases, affect different functional aspects of the drug. Mu 
opioid actions are dependent on both biased signaling as well as the 
splice variant mediating the function.  
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